前往化源商城

486-79-3 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:AR protein [Homo sapiens]
External ID: MDAN535
Protocol: Please refer to other AIDs 743042 and 743041 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the AR antagonist mode assay (AID 743042) and cell viability counter screen (AID 743041). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryAR ActivityAR Potency (uM)AR Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inconclusive agonistinconclusive agonistinactive0NCI
inconclusive antagonist (cytotoxic)active antagonist18.12455735-111.5015527active antagonist20.3992366-95.33077837NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist33.49145963-71.97733202active antagonist33.49145963-45.59717193SigmaAldrich
inconclusive antagonist (cytotoxic)active antagonist24.63773286-89.63619394inconclusive antagonist33.49145963-42.65251674NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist30.2961402-37.60775273NCI
inactiveinactive0inconclusive antagonistLabotest
active antagonistactive antagonist28.72548756-74.97879422inconclusive antagonist32.33061121-27.15821987NCI
active antagonistactive antagonist27.64399095-64.36631028inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)inconclusive antagonist33.49145963-64.79576401active antagonist32.7130197-37.67340069NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
inconclusive agonistinconclusive agonistinactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: MDAV150
Protocol: Tox21 Assay Protocol Summary:

MDA-kb2 AR-luc cells were dispensed at 3,000 cells/4 uL/well of culture medium into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 0% CO2 for 5 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 0% CO2 for 16 h. After 15.5 h incubation, 1uL of CellTiter-Fluor reagent (Promega) was added using a Bioraptr FRD to each plate for measuring cytotoxicity. The fluorescence intensity was quantified on a ViewLux plate reader (PerkinElmer, Shelton, CT) following 30 min incubation at 37C and 0% CO2.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002746821 uM-Replicate_1Activity at 0.0005960927 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.16 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.95 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.9341-4.0025-4.45586.8198-1.1644-4.92122.01380.18830.932-6.078-2.34493.01673.4002-5.54413.9341QC'd by NCIInactive04.50450.56978
Cytotoxic15.6421110.147982Complete curve; high efficacy-4.80572.72020.9603-107.6072.5408-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0-95.90644.73640.534-1.15171.49885.7269-3.13844.6023-2.5915.101-0.7039-0.1448-2.8091-85.7578-95.9064QC'd by NCICytotoxic26.603280.513740Partial curve; high efficacy-4.57513.1320.9819-78.1328
Inactive00.30.5018-6.6712640 0 0 0 0 0 0 0 0 0 0 0 0 0-4.483807.84125.0947-0.36850.9766-4.3547-0.66533.21310-2.6766-3.7672-6.3927-2.7561-4.4838QC'd by NCIInactive0
Cytotoxic33.491553.023520Single point of activity-4.47514.95490.9093-57.314-4.2905-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.2755-6.13-5.7216-6.0909-1.1322-4.0113-6.953-0.8667-0.5352-3.8081-2.7523-6.4736-0.2391-14.0348-4.1839-50.2755QC'd by SigmaAldrichCytotoxic33.491543.216120Single point of activity-4.47514.95490.9489-44.7217
Inactive03.06540.64480.20834.321840 0 0 0 0 0 0 0 0 0 0 0 0 0-18.894333.038234.043-6.70165.11124.24770.05467.51211.52441.08954.9424.91169.6713-8.8416-18.8943QC'd by NCICytotoxic33.491538.402820Single point of activity-4.47514.95490.832-38.6215
Inactive04.95490.7541-3.03628.540 0 0 0 0 0 0 0 0 0 0 0 0 0-1.65425.818611.123-2.6648-5.527-2.1108-0.7834-0.2795-1.3292-6.2801-5.9904-3.6693-1.3675-3.1321-1.6542QC'd by NCIInactive04.95490.3332-0.5
Inactive04.95490.84961.39232240 0 0 0 0 0 0 0 0 0 0 0 0 04.046617.94353.1030.41822.1955-0.17152.82353.96390.0788-0.239-2.58983.38281.79160.39744.0466QC'd by NCIInactive04.50450.9224-0.7305
Inactive03.51170.39273-1.695140 0 0 0 0 0 0 0 0 0 0 0 0 0 02.3532-0.7162-0.0074-1.51420.6742-1.9219-3.891-3.1053-2.3524-2.8619-0.949-1.1980.6682-4.74592.1422.3532QC'd by NCIInactive0
Cytotoxic31.2143.456620Single point of activity-4.50574.95490.7461-46.3321-2.8755-30 0 0 0 0 0 0 0 0 0 0 0 0 0-45.4236-23.2298-4.49953.3316-2.32112.1332-2.31951.5412-1.1787-5.146-0.56271.3154-5.0727-6.7293-45.4236QC'd by NCICytotoxic26.603238.826420Partial curve; partial efficacy-4.57513.1320.8519-40.8264
Cytotoxic26.603234.702920Partial curve; partial efficacy-4.57512.40640.9771-38.2666-3.5637-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.0555-4.6672-2.5088-5.4716-4.3602-4.1809-2.6891-4.1367-1.8067-1.3031-4.0865-2.8527-4.2279-4.8434-16.0218-31.0555QC'd by LabotestInactive03.06540.7575-18.2037
Cytotoxic31.2126.94420Partial curve; partial efficacy; poor fit-4.50574.95490.8037-24.9442-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-24.1210.59991.3585-0.3563-0.60562.1079-1.54786.16642.4623-1.89281.97841.18620.52481.7585-24.12QC'd by NCICytotoxic33.491527.372520Partial curve; partial efficacy; poor fit-4.47514.95490.8005-26.3725
Inactive01.62660.7987-19.85024.540 0 0 0 0 0 0 0 0 0 0 0 0 0-14.87519.4894-1.33438.71942.60745.36513.28525.9036.96833.64690.0211-0.04561.4841-14.2523-14.8751QC'd by NCIInactive0
Inactive047.36137.5196-7.3951-0.70231.14315.96320.48820.14911.02055.83171.3822-0.343410.53266.96547.3613QC'd by NCIInactive0
Cytotoxic31.2131.422720Single point of activity-4.50574.95490.8431-33.9227-2.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0-33.2689-9.9006-5.5288-1.4219-0.0243-6.7803-3.4216-2.11071.4914-3.4573-1.8023-3.3297-0.1019-0.8542-33.2689QC'd by NCICytotoxic33.491551.227920Single point of activity-4.47514.95490.8738-54.2347
Inactive048.1128-3.52191.60923.5704-3.05675.54251.1281.79473.9211.45843.09545.7098-1.1492.90538.1128QC'd by NCIInactive0
Inactive04.95490.54013-7.823740 0 0 0 0 0 0 0 0 0 0 0 0 01.1178-1.9427-14.01981.42342.61488.01592.12438.1348-0.05886.06141.26242.49191.59630.22081.1178QC'd by NCIInactive0
Inactive043.42253.6223-3.44319.3218-0.1732-0.80331.8093-2.39193.81192.1766-1.5835-1.20313.85931.62713.4225QC'd by NCIInactive04.95490.38771
Inactive04.95490.42743.5-1.818940 0 0 0 0 0 0 0 0 0 0 0 0 0 04.6673-1.0353-6.09910.1105-0.7736-1.0905-3.54160.56970.18692.2758-5.4321-2.2238-3.56285.220.99214.6673QC'd by ChembridgeInactive0
Cytotoxic27.815930.261720Partial curve; partial efficacy; poor fit-4.55574.95490.7703-27.76172.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-26.4681-2.20990.61468.7045-3.0357-3.4205-0.0515-0.023510.83455.83643.293.32762.2442-2.1893-26.4681QC'd by NCIInactive04.95490.7812-21.5734
Inactive04-7.12970.2395-3.92457.56442.93285.83127.2431-2.9052-0.36468.84164.56552.17381.58961.9706-7.1297QC'd by NCIInactive04.50450.5518-8.9683
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:IucA Synthetase from hypervirulent Klebsiella pneumoniae hvKP1
External ID: IucA Pilot Assay Spectrum Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
1.054109.5793076877485A04
1.048108.5123881216295A05
1.085115.0917254460325A06
1.154127.3613004564045A07
1.12121.3154229150615A08
1.115120.4263232766295A09
1.126122.3823424811815A11
1.154127.3613004564045A12
1.138124.5161816134195A13
1.17130.2064192993895A14
1.155127.5391203840915A16
1.128122.7379823365545A17
1.156127.7169403117785A18
1.053109.4014877600625A19
1.052109.2236678323755A20
1.067111.8909667476735A21
1.032105.6672692786445A22
1.062111.0018671092415B03
1.091116.1586450121515B06
1.108119.1815837828235B08
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11924 靶标:N/A
External ID: CGM data for Cell Systems paper Dec 2015
Protocol: Yeast strains and Media:
All S. cerevisiae deletion strains were obtained from the Euroscarf deletion collection. The wild type parental strain for this collection is BY 4741 MATa his31 leu20 met150 ura30. An isogenic pdr1pdr3 strain (MT2481) was created using PDR1::nat and PDR::URA3 deletion cassettes. All strains were grown and screened in synthetic complete (SC) medium with 2% glucose.

Handling:
Strains were seeded at 50,000 cells per well in a volume of 100 L in 96 well plates followed by addition of 2 L of 1 mM compound stock for final concentration of 20 M. Screens were conducted in technical duplicate using a Biomek FX liquid handling workstation with an integrated stacker carousel. DMSO solvent only controls and 10 uM cycloheximide positive controls were seeded in columns 1 and 12 of each assay plate. Plates were incubated at 30 C without shaking for approximately 18 h or until culture saturation was achieved for the solvent controls. Cultures were resuspended by shaking on the robotic platform prior to reading OD600 values on either Tecan M1000 or Tecan Sunrise plate readers.

Analysis procedure:
All data was subjected to the following workflow:
1. Consistent spatial effects on growth across plates were corrected by Lowess regression using an empirically estimated sliding window of 1/3 and normalized based on plate median.
2. If more than 30% of compounds were active within a plate, data was normalized to DMSO controls.
3. Median normalization was applied to all plates and experiments.
4. Z-factors for growth inhibition were calculated using the median and the interquartile range (IQR) by fitting a normal distribution with N(1,IQR) to the experimental data. In addition, we calculated the Z-factor, percent inhibition and normalized OD values for manual validation.
5. Data points with high variation between replicates (> 3 MAD) were removed as inconsistent outliers.

BioAssay submission file header:

Pubchem_ext_datasource_regid: compound identifier used in on chemgrid.org/cgm
Orf yeast gene deletion (open reading frame)
Sym# yeast gene deletion gene symbol
Raw OD read 1 first replicate
Raw OD read 2 second replicate
Normalized OD average normalized read based on workflow described above
Z_score Z-Score calculated based on kernel density distribution from normalized average reads per screen
P_value p-value calculated based on kernel density distribution calculated from average reads per screen
Non replicate test for non-replicates between first and second replicate
Pubchem_activity_outcome pubchem activity outcome
Cryptagen if compound identifier fulfilled cryptagen rule of activity in at least 4 and not more than 2/3rds of screens per library
Bioactivity sensitive if compound decreases fitness or resistant if compound increases fitness compared to negative control
Comment:
orfsymraw OD read 1raw OD read 2normalized OD averagez_scorep_valuenon replicatecryptagenbioactivity
YMR263WSAP300.81090.82411.007920.6765250.25126700
YMR263WSAP300.70740.70450.999472-0.02700660.43853300
YMR263WSAP300.71320.82811.017960.6225070.27234601
YMR263WSAP300.80970.70871.008750.7614850.22641600
YMR263WSAP300.69810.82591.01050.3744620.35427900
YMR263WSAP300.80850.70631.005020.4370360.33193100
YMR263WSAP300.65350.68970.990762-0.3283280.37139400
YMR263WSAP300.81330.69411.007170.5988890.29095200
YMR263WSAP300.68670.80190.976773-0.8247460.20524700
YMR263WSAP300.78360.68620.991018-0.7716340.22038900
YMR263WSAP300.59950.61390.893377-3.803870.00037803201
YMR263WSAP300.62710.80940.962532-1.306830.10774100
YMR263WSAP300.68780.69570.980366-0.6848680.24993400
YMR263WSAP300.68680.69620.978746-0.7416890.23281100
YMR263WSAP300.65410.64840.937529-2.232410.02007301
YMR263WSAP300.81210.82591.009720.8309410.20515300
YMR263WSAP300.68160.69681.002080.06816690.4595700
YMR263WSAP300.70580.79830.990309-0.3607950.36655800
YMR263WSAP300.78730.80340.980792-1.660550.049953200
YMR263WSAP300.69170.70120.997639-0.08757040.46520801
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=ATPase family AAA domain-containing protein 5; AltName: Full=Chromosome fragility-associated gene 1 protein
External ID: ELG271
Protocol: Please refer to other AIDs 651632 and 651634 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the ATAD5 assay (AID 651632) and cell viability counter screen (AID 651634). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryATAD5 ActivityATAD5 Potency (uM)ATAD5 Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active agonistactive agonist19.3311819612.17977568inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0TCI
inactiveinactive0inactive0Alfa Aesar
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inconclusive antagonistinconclusive antagonist-22.16843258active antagonist30.63785869-80.36907549SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24386 靶标:N/A
External ID: Sarm1 Tir NADase inhibitors screen
Protocol: NRK1-HEK293T cells were seeded onto 150 cm2 plates at 20 x 106 cells per plate. The next day, the cells were transfected with 15 microg FCIV-SST (SAM-TIR expression plasmid) using X-tremeGENE 9 DNA Transfection Reagent (Roche product #06365787001). The cultures were supplemented with 1 mM nicotinamide riboside at time of transfection to minimize toxicity from SAM-TIR overexpression. Forty-eight hours after transfection, cells were harvested, pelleted by centrifugation at 1,000 rpm (Sorvall ST 16R centrifuge, Thermo Fisher), and washed once with cold PBS (0.01 M phosphate buffered saline NaCl 0.138 M; KCl 0.0027 M; pH 7.4). The cells were resuspended in PBS with protease inhibitors (Complete protease inhibitor cocktail, Roche product # 11873580001) and cell lysates were prepared by sonication (Branson Sonifer 450, output = 3, 20 episodes of stroke). The lysates were centrifuged (12,000xg for 10 min at 4 degrees C) to remove cell debris and the supernatants (containing SARM1 SAM-TIR protein) were stored at -80 degrees C for later use in the in vitro SARM1 SAM-TIR NADase assay (see below). Protein concentration was determined by the Bicinchoninic (BCA) method.

This screen is an adaptation of the NAD/NADH Glo assay (Promega G9071). In this assay, NAD cycling enzymes convert NAD into NADH. In the presence of NADH, the reductase enzymatically converts a proluciferin reductase substrate into luciferin. Luciferin is detected using Ultra-GloTM rLuciferase, and the chemiluminescence intensity is proportional to the amount of NAD and NADH in the sample. In our diluted lysate alone, the amount of NAD and NADH is undetectable with this assay precluding any endogenous contribution to the final NAD detected. The assay was set up as follows: 2 microl candidate inhibitor (final concentration 1 microM, 2% DMSO), 0.07 microg lysate (2 microl), and 2 microl of 400 nM NAD. The reaction was incubated at 37 degrees C for 60 min, then 6 microl NAD/NADH Glo detection reagent was added. After 30 min at room temperature, the luminescent signals were quantified using a Cytation5 imaging reader (BioTek). The SARM1 SAM-TIR lysate catalyzed a dose-dependent depletion of NAD, whereas NAD levels did not decline when reactions were performed with lysate prepared from control NRK1-HEK293T cells.
Comment:
NAD(nM)
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:thyroid hormone receptor beta isoform 2 [Rattus norvegicus]
External ID: TRN186
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37 C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo Luciferase Assay reagent (Promega) was added to each well using a Bioraptr FRD (Beckman Coulter), followed by 30 min incubation at room temperature. The luminescence intensity of plates was recorded by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.0950.3471-11.4032.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.50250.1158-3.1697-0.33515.6720.861714.90173.38536.9176-0.23470.4322-0.26143.98420.0305-0.2471-9.5025QC'd by NCIInactive0
Inhibitor8.4127111.383Complete curve; high efficacy-5.07514.50450.9828-108.24563.0545-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-112.7558-1.15723.06639.00343.54455.92481.74539.42291.34811.146-12.38566.95031.0946-61.7744-103.2834-112.7558QC'd by NCIInhibitor11.8832114.52442Partial curve; high efficacy-4.92512.95230.9725-113.8942
Inhibitor33.4915108.428710Single point of activity-4.47514.95490.9805-106.41752.0112-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.3487-0.0130.29265.8092.3543-1.529-1.86081.7268-1.32142.07110.45466.4268-1.17365.0616-1.2831-93.3487QC'd by NCIInhibitor33.491545.255310Single point of activity-4.47514.95490.8805-44.8499
Inhibitor6.6824112.359884Complete curve; high efficacy-5.17512.72020.9976-112.35980-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-107.86851.8367-0.98520.055-0.0873-0.0192-0.22741.70630.4571-0.0314-1.0907-6.2723-21.2839-82.4952-110.1566-107.8685QC'd by SigmaAldrichInhibitor11.8832118.081443Partial curve; high efficacy-4.92511.80790.9544-118.7095
Inhibitor6.6824105.669684Complete curve; high efficacy-5.17514.95490.9938-106.8079-1.1383-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-105.07267.23320.2468-0.2504-1.5237-2.6002-3.7474-7.12-3.24092.46950.0289-2.5534-12.3799-89.7924-106.5947-105.0726QC'd by NCIInhibitor9.4392121.220283Complete curve; high efficacy-5.02513.990.9879-117.3663
Inactive01.39870.58200.743840 0 0 0 0 0 0 0 0 0 0 0 0 0 16.5615-1.2435-1.42584.69634.22561.3627-6.880211.4156-5.29793.471-0.63623.942610.207711.431217.98796.5615QC'd by NCIInactive04.95490.50497
Inactive048.6584-0.25360.6070.1862-7.14463.14683.8879-0.6670.72263.43975.19140.62353.6739-0.02550.89198.6584QC'd by NCIInactive00.80.38469
Inactive0410.54210.43950.42364.47171.1049-1.458613.91965.5002-1.05963.065-7.07060.06181.202510.164811.16310.5421QC'd by NCIInactive03.990.606418
Inactive04-2.79550.91070.63340.0441-1.57746.62466.8752-6.6198-1.914714.01640.09133.5513.40912.4192-0.0362-2.7955QC'd by NCIInactive01.82650.72117
Inhibitor29.849398.496140Partial curve; high efficacy-4.52512.58840.9136-98.06750.4287-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-74.29356.770611.4199-0.0327-7.65161.0084-7.6141-0.0057-4.1882-0.0137-5.30869.05936.513-11.2634-24.6953-74.2935QC'd by LabotestInhibitor23.710181.201341Partial curve; high efficacy-4.62511.62660.9814-85.328
Inhibitor11.8832113.855282Complete curve; high efficacy-4.92513.51170.9826-115.6541-1.7989-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-108.9022-2.57351.71220.0161-0.9518-6.581711.0269-0.7611-7.71670.0417-2.5311-7.3404-6.9128-34.9326-107.0686-108.9022QC'd by NCIInhibitor13.3332117.674582Complete curve; high efficacy-4.87513.1320.9752-119.5106
Inhibitor11.8832100.560342Partial curve; high efficacy-4.92512.30310.9844-98.40762.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.4781-3.68021.45591.078-0.28983.594211.15550.03471.61545.5371-0.609-0.03380.0197-37.731-72.8614-96.4781QC'd by NCIInhibitor11.8832104.835482Complete curve; high efficacy-4.92512.84730.9729-101.2413
Inactive049.109716.353612.83932.63922.84184.686310.95966.499811.73249.79221.807413.675211.786911.24189.60329.1097QC'd by NCIInactive04.95490.571320.5
Inhibitor9.4392111.014483Complete curve; high efficacy-5.02513.06540.9851-108.05722.9572-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-104.01842.36323.22810.98985.081712.35020.2029-2.0107-1.81368.62391.97771.5258-9.3399-43.8626-105.9384-104.0184QC'd by NCIInhibitor11.8832117.796983Complete curve; high efficacy-4.92513.51170.9855-119.6341
Inactive01.10.49998.50.760140 0 0 0 0 0 0 0 0 0 0 0 0 0 06.7333-1.17177.005-0.40612.2711-1.86660.092310.02274.12186.31389.59344.80676.54059.438813.04816.7333QC'd by NCIInactive03.51170.516322
Inhibitor23.710130.537110Partial curve; partial efficacy; poor fit-4.62514.44950.7197-30.53710-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.1975-0.68221.0324-2.45350.1458-0.1477-0.2161-13.6864-3.44241.79450.06561.3783.68649.5588-10.7074-29.1975QC'd by NCIInactive04.95490.9007-21.9629
Inactive0413.5114-0.54170.0115-0.029211.3153-0.00342.57815.33694.0109-1.29990.1952.6113-0.1351-0.43365.290313.5114QC'd by NCIInactive00.80.552326
Inactive040.5778-0.8927-0.3832-2.6058-1.17790.83535.6138-2.89484.8776-1.355-0.2164-10.3629-1.68473.3283-2.910.5778QC'd by ChembridgeInactive0
Inhibitor26.603248.396120Partial curve; partial efficacy-4.57514.95490.9177-49.2222-0.826-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.4351-2.3640.3688-9.6388-2.3442-2.041-0.00221.4733.1991-2.8675-0.6678-2.01651.02016.8251-11.741-46.4351QC'd by NCIInhibitor26.603240.019410Single point of activity-4.57514.95490.7816-36.0194
Inhibitor21.131779.094741Partial curve; high efficacy-4.67513.51170.7387-73.1775.9177-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.1538-0.9821-2.4893-8.8857-2.70951.21070.3298-0.1518-3.40975.743516.504521.713139.4410.1435-33.7222-68.1538QC'd by NCIInhibitor33.491568.810410Single point of activity-4.47514.95490.782-64.8654
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: TRV455
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.95490.51575.6094-10.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-27.8709-9.58131.553-23.1602-8.9484-8.346419.02864.562714.53951.15650.42210.27193.49757.10181.1664-27.8709QC'd by NCIInactive0
Cytotoxic11.8832114.332782Complete curve; high efficacy-4.92513.92950.9541-100.920113.4126-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.18524.113126.147419.56668.33238.270922.114823.359311.62112.5923-0.271521.57888.2783-15.4501-95.7853-95.1852QC'd by NCICytotoxic13.3332101.165782Complete curve; high efficacy-4.87513.51170.924-104.4065
Cytotoxic33.491569.601420Single point of activity-4.47514.50450.5249-51.740917.8605-30 1 0 0 0 0 0 0 0 0 0 0 0 0 0-39.633934.934439.865511.20360.12813.12894.307410.103240.163543.97149.337135.80113.21470.805410.5036-39.6339QC'd by NCIInconclusive10.590945.114210Single point of activity-4.97510.80.518447.3375
Cytotoxic8.412795.006983Complete curve; high efficacy-5.07511.96730.9579-102.9662-7.9593-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-94.1612-1.6767-10.7501-18.3328-8.44320.3012-1.3116-10.0891-5.1512-10.2638-22.1904-3.3436-24.9807-62.5458-94.2914-94.1612QC'd by SigmaAldrichCytotoxic11.883290.158242Partial curve; high efficacy-4.92511.59360.9327-91.6733
Cytotoxic7.497881.846383Complete curve; high efficacy-5.12512.33320.9281-89.6388-7.7925-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-91.0963-18.97671.8287-17.872-12.3952-7.6161-16.3335-2.8335-2.6272-3.7796-9.8936-2.6598-12.2011-70.0356-74.6023-91.0963QC'd by NCICytotoxic7.497889.379383Complete curve; high efficacy-5.12512.40640.958-91.4223
Inactive049.32249.077510.90740.011913.6377.6888-14.85723.0077-6.11470.1121-5.92519.31916.946521.403721.67069.3224QC'd by NCIInactive0
Inactive048.728114.5817-0.06687.0683-0.16080.00131.578912.1056-2.13575.0113.2012-0.24876.3162-7.20095.40878.7281QC'd by NCIInactive04.95490.3678-32.6446
Inactive01.96730.466926.51032.587640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.33589.20266.9567-7.84944.72089.308420.04687.737-11.6312.3017-13.68133.162210.305816.449622.830726.3358QC'd by NCIInactive03.06540.3751-0.4202
Cytotoxic26.603233.620Partial curve; partial efficacy; poor fit-4.57513.990.6032-35.6-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.1667-19.4025-0.1543-0.2262-0.0757-11.09324.6638-6.5718-3.54455.09010.036-2.1840.10135.1383-12.1502-32.1667QC'd by NCIInactive0
Cytotoxic29.849380.614440Partial curve; high efficacy-4.52513.24750.7249-82.8026-2.1882-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.04879.32489.4674-17.343-9.0088-18.8502-4.8122-4.1352-5.0412-6.7317-5.864410.034619.8329-8.8964-20.6155-67.0487QC'd by LabotestCytotoxic29.849363.527240Partial curve; partial efficacy-4.52512.72020.9071-66.8238
Cytotoxic13.3332104.692182Complete curve; high efficacy-4.87513.51170.9601-100.33534.3568-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.17277.15452.81146.9308-0.1572-4.105825.3068-0.15731.08666.05980.85484.7774-0.6992-14.6485-90.6892-99.1727QC'd by NCICytotoxic16.7855114.729642Partial curve; high efficacy-4.77512.25260.9303-115.7849
Cytotoxic26.603293.069640Partial curve; high efficacy-4.57512.58840.7505-86.42426.6454-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.9291-25.457521.195211.0147-3.417213.682328.16354.114810.73649.90963.39471.32276.46260.2705-23.9356-68.9291QC'd by NCICytotoxic26.603283.904440Partial curve; high efficacy-4.57513.62720.9084-83.7035
Inactive0418.582530.92839.765411.01316.57590.04867.97495.3184.25971.95691.324516.866511.719816.94696.665118.5825QC'd by NCIInactive0
Cytotoxic10.590994.271582Complete curve; high efficacy-4.97512.72020.9664-98.4917-4.2203-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.2687-12.6266-9.71552.76191.16913.9341-2.1458-8.3456-7.78480.2987-4.4158-14.4266-11.7198-37.3785-91.2452-93.2687QC'd by NCICytotoxic10.590995.537682Complete curve; high efficacy-4.97512.40640.9837-98.3736
Inactive0421.512319.121525.006-1.94118.35391.0147-1.112212.94014.543614.711516.23313.403818.402626.76119.601221.5123QC'd by NCIInactive0
Inactive02.53340.618314.3567-5.901840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9449-6.97990.27957.2032-12.5846-2.9847-20.5724-7.1225-1.8195.056311.806413.728118.906723.71122.022-7.9449QC'd by NCICytotoxic33.491533.929720Single point of activity-4.47514.95490.5032-33.6955
Inactive0422.09676.01187.77648.964524.48872.336215.856811.60168.99512.18910.87535.056316.9556-9.06529.599522.0967QC'd by NCIInactive02.24810.359418.3831
Inactive04.95490.412622-0.482840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.1783-1.3463-1.5399-1.530212.584-0.6727.8822-4.87790.9615-0.7224-1.1373-9.9856-1.498-1.70110.588816.1783QC'd by ChembridgeInactive0
Cytotoxic29.849359.759320Single point of activity-4.52514.95490.7823-51.55738.202-30 0 0 0 0 1 0 0 0 0 0 0 0 0 0-45.047813.2325.4558-6.067513.70124.8368-25.68159.851213.6578.28768.3941-6.470517.960418.9919-1.1526-45.0478QC'd by NCICytotoxic33.491560.182320Single point of activity-4.47514.95490.9381-56.7139
Cytotoxic33.491577.960640Partial curve; high efficacy-4.47513.51170.6902-85.5053-7.5447-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.8614-23.92-6.4036-24.81696.0929-7.6795-2.09631.7283-20.9170.4558-10.7547-17.85467.586-12.7766-19.5831-67.8614QC'd by NCICytotoxic33.491567.176140Partial curve; high efficacy-4.47514.95490.7237-73.9128
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:N/A
External ID: 7124-01_Inhibitor_SinglePoint_HTS_Activity
Protocol:
Protocol:
1) Plate 10 uL BL2-NFkB-luc cells at 12.5K cells/well, using a Multidrop Combi reagent dispenser (1,250 cells/uL).
2) Add 25 nL compound or positive control, by pin transfer; IKK inhibitor VII will be used at 50 uM.
3) Incubate at 37 masculineC for 1 hour (allowing compounds to enter cells for action).
4) Add 5 uL 192 ng/mL tCD40L per well for a final concentration of 64 ng/ml using a Thermo Multidrop Combi.
5) Incubate at 37 masculineC for 4 hrs, then leave plate at RT for 30 minutes.
6) Add 15 uL SteadyGlo luciferase substrate (Promega) per well using a Thermo Multidrop Combi.
7) Incubate at RT for 5min, then read Luminescence using LJL Analyst HT plate reader.
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in decreasing readout signal.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Neutral Controls Minus Inhibitors' method in Genedata Assay Analyzer (v10.0.2):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of -100.
Experimental wells values were scaled to this range.

PATTERN CORRECTION: No plate pattern correction algorithm from Genedata Condoseo (v.10.0.2) was applied.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized sample replicate activities, rounded to the nearest integer .
The minimum PUBCHEM_ACTIVITY_SCORE required for a compound to be called a hit (the activity threshold, or AT) was set at -50.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at 55.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 1 (inactive) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

Samples passing PAR_T only were assigned an outcome of 1 (inactive) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_10uM_(%)REPLICATE_B_ACTIVITY_SCORE_10uM_(%)REPLICATE_C_ACTIVITY_SCORE_10uM_(%)REPLICATE_D_ACTIVITY_SCORE_10uM_(%)REPLICATE_A_ACTIVITY_SCORE_25uM_(%)REPLICATE_B_ACTIVITY_SCORE_25uM_(%)
0.79620-2.349-0.32
105.6735.654
0.992109.2477.171
1010.26510.389
0.99270-11.538-9.04
004.22
0.988401.71.248
0.859020.4545.179
0.572505.367-0.953
0.980-5.16-7.79
0.95509.6865.096
0.68210-13.0050.453
0.875408.3542.409
0.9468011.7385.785
0.98530-15.255-10.751
0.5260-1.7597.464
0.84350102.218
0.9897019.1614.325
10-28.597-28.833
0.993506.7018.436
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Broad Institute 靶标:histone-lysine N-methyltransferase EZH2 isoform a [Homo sapiens]
External ID: 2125-01_Inhibitor_SinglePoint_HTS_Activity
Protocol: Protocol:
PRC2 activity was measured using Dissociation-Enhanced Lanthanide Fluoro-ImmunoAssays (DELFIA) performed on 384-well, white, streptavidin-coated plates (PerkinElmer). In short, PRC2 was diluted to 30 ng and 3 ng per well in 20 uL 2X Enzyme Buffer (50mM Tris HCl pH 8.5, 10 mM DTT, 5 mM MgCl). Compounds were pinned at 100 nL per well and reactions were initiated with 20 uL of a 5 uM SAM (NEB) solution containing 600 nM H3[21-44]-GK-biotin (AnaSpec; PRC2).

Plates were incubated at room temperature for 1 hr and then washed three times with 100 uL of Wash Buffer (50mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween 20, 0.2% BSA). 50 ul of Fluoroimmunoassay (FI) Buffer (50 mM Tris HCl pH 7.8, 150 mM NaCl, 0.05% Tween 40, 25 iM DTPA, 0.2% BSA, 0.05% BGG)containing a 1:4000 dilution of anti-H3K27me2 rabbit IgG (Cell Signaling, #9728) with 691 ng/mL Eu-N1-anti-rabbit IgG (PerkinElmer)was added to each well for PRC2 reactions.

Following 1 hr incubation at room temperature, the plates were washed three times with Wash Buffer and 50 uL of Enhancement Solution (PerkinElmer) was added to each well. Plates were incubated for 30 min at room temperature and time-resolved fluorescence (TRF) was measured on Wallac Envision 2104 Multilabel Reader (400 us window, 400 us delay, 320 excitation, 615 emission).
Comment: PRESENCE OF CONTROLS: Neutral control wells (NC) and positive control wells (PC) were included on every plate.

EXPECTED OUTCOME: Active compounds result in decreasing readout signal.

NORMALIZATION:
The raw signals of the plate wells were normalized using the 'Neutral Controls Minus Inhibitors' method in Genedata Assay Analyzer (v7.0.3):
The median raw signal of the intraplate neutral control wells was set to a normalized activity value of 0.
The median raw signal of the intraplate positive control wells was set to a normalized activity value of -100.
Experimental wells values were scaled to this range.
All well activities were then multiplied by -1 to create a positive activity readout value range, to match Pubchem convention.

PATTERN CORRECTION: No plate pattern correction algorithm from Genedata Condoseo (v.7.0.3) was applied.

PUBCHEM_ACTIVITY_SCORE:
This was set as equal to the mean of the normalized sample replicate activities, rounded to the nearest integer .
The minimum PUBCHEM_ACTIVITY_SCORE required for a compound to be called a hit (the activity threshold, or AT) was set at 50.

PERCENTAGE OF ACTIVE REPLICATES:
For each sample, the percentage of replicates (PCT_ACTIVE_REP) which had activity scores >= AT was determined.
The minimum percentage of replicates required for a compound to be called a hit (PAR_T) was set at 100.

PUBCHEM_ACTIVITY_OUTCOME:
Samples passing BOTH threshold criteria were assigned an outcome of 2 (active):
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP >= PAR_T

Samples passing NEITHER threshold criteria were assigned an outcome of 1 (inactive):
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP < PAR_T

Samples passing AT only were assigned an outcome of 3 (inconclusive) :
PUBCHEM_ACTIVITY_SCORE >= AT, and PCT_ACTIVE_REP < PAR_T

Samples passing PAR_T only were assigned an outcome of 1 (inactive) :
PUBCHEM_ACTIVITY_SCORE < AT, and PCT_ACTIVE_REP >= PAR_T
REPRODUCIBILITY_COSINE_TRANSFORMPCT_ACTIVE_REPLICATESREPLICATE_A_ACTIVITY_SCORE_12.5uM_(%)REPLICATE_B_ACTIVITY_SCORE_12.5uM_(%)
000.193
00-0.443
000.02
00-10.883
003.986
0016.236
0038.043
003.387
0013.272
00-0.209
000.757
002.786
00-12.234
00-10.048
001.844
00-2.259
00-8.602
001.219
006.005
0013.086
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: cmt-p4-fda-celltiter_regid
Protocol: Native S16 cells were seeded in white solid-bottom 1536 well plates at between 500-750 cells/6uL in DMEM medium containing 10% FBS, w/o phenol red. After overnight incubation at 37 degree Celsius/5% C02, 23 nL of compounds or DMSO were delivered to each well using a pin tool, followed by 24h-incubation at 37 degree Celsius/5% C02. Then one volume of CellTiter-Glo assay reagent (Promega) was added to each well for cell viability measured by a ViewLux plate reader (PerkinElmer). The % activity was determined by normalizing to the average readings from wells containing no cells relative to DMSO-treated cells (0% Activity). The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, toxic compounds are ranked higher than non-toxic compounds.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Toxic compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001640000 uMActivity at 0.0007350000 uMActivity at 0.0008220000 uMActivity at 0.00164 uMActivity at 0.00382 uMActivity at 0.00822 uMActivity at 0.019 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.206 uMActivity at 0.477 uMActivity at 1.030 uMActivity at 2.387 uMActivity at 5.336 uMActivity at 11.50 uMActivity at 25.70 uMActivity at 57.50 uMCompound QC
Inactive04-5.0009-3.85828.5637.7356-2.60638.8494-2.90027.3097-5.0009QC'd by "Chemical Block"
Inactive0-6.34224.95490.5937-12.668213.847440 0 0 0 0 0 0 0-1.069212.3719020.129923.1735-20.7201-28.56350-1.0692QC'd by "NIEHS"
Inactive0-6.94224.95490.5344-2.6603940 0 0 0 0 0 0 0-2.95733.5518.201815.5837-3.49380.18554.8403-11.8003-2.9573QC'd by "Bionet"
Inactive0-8.14220.70.37485.5-3.325140 0 0 0 0 0 0 07.3531-1.93763.13311.23193.911811.65780.794.15327.3531QC'd by "Microsource"
Inactive0-8.34221.1110.50428.5-8.207740 0 0 0 0 0 0 1-0.1414-5.17314.41623.99997.96518.56314.17684.9224-0.1414QC'd by "SigmaAldrich"
Cytotoxic9.074338.445721Complete curve; partial efficacy-5.04223.67720.9534-30.61847.8273-1.20 0 0 0 0 0 0 0-31.20485.95771.410115.34117.31819.36473.7902-29.5419-31.2048QC'd by "BIOMOL"
Inactive04-1.1093.12850.95515.46465.5291-22.30798.65081.0562-1.109QC'd by "BIOMOL"
Inactive0-4.64222.04370.4724-12.25234.540 0 0 0 0 0 0 0-10.2103-2.8783-1.96848.16842.652216.10652.7958-5.0963-10.2103QC'd by "Microsource"
Inactive04-35.0613-10.1978-31.4679-21.1443-10.6505-13.0426-18.8828-22.614-35.0613QC'd by "SigmaAldrich"
Inactive04-0.43678.5443-1.90230.867411.703712.903511.67040.94-0.4367QC'd by "BIOMOL"
Inactive0-8.29221.10.70078.5-4.990140 0 0 0 0 0 0 1-2.7665-2.49174.50735.70939.147311.094311.54643.6682-2.7665QC'd by "Microsource"
Inactive04-23.26811.1336-28.53635.73076.3285-1.73042.4702-11.2804-23.2681QC'd by "BIOMOL"
Inactive0-5.64224.95490.5184-0.1857740 0 0 0 0 0 0 17.08570.447811.22575.64758.42318.0861-0.98810.29837.0857QC'd by "BIOMOL"
Inactive0416.40688.443411.318421.924627.44418.887710.570822.657716.4068QC'd by "BIOMOL"
Inactive0-8.64224.95490.90670.5-21.968840 0 0 0 0 0 0 1-18.1607-18.30732.5460.7431-0.64421.9512.9894-3.7133-18.1607QC'd by "SigmaAldrich"
Inactive0-7.79224.0950.60476-4.042940 0 0 0 0 0 0 1-6.0398-4.2024-3.33235.561713.5456.78374.27220.3922-6.0398QC'd by "SigmaAldrich"
Inactive0-8.44223.24750.6851-5.60992140 0 0 0 0 0 0 0019.0978-3.8976-10.2909-16.7583-7.9421000QC'd by "BIOMOL"
Inactive048.3767-0.84056.581514.3275-0.043416.57681.30653.99668.3767QC'd by "BIOMOL"
Inactive047.7788.1853-2.3072-1.044911.73596.1253-2.342211.7587.778QC'd by "NIEHS"
Cytotoxic32.196895.472540Partial curve; high efficacy-4.49224.95490.992-92.72312.7494-2.10 0 0 0 0 0 0 0-88.30773.5692-1.34043.36762.4201-1.00816.7043-17.8812-88.3077QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Luciferase [Photinus pyralis]
External ID: adst-fluc-km-fda-o1_regid
Protocol: Three microliters/well of substrate- buffer solution (0.01 mM D-Luciferin, 0.01 mM ATP, 50 mM Tris Acetate, 10 mM Mg Acetate, 0.01% Tween-20 and 0.038% BSA final concentrations) were dispensed into white solid-bottom 1536 well plates. Compounds were transferred to the plates in 23nl, and one microliter/well luciferase enzyme-buffer solution (10 nM P. pyralis luciferase and 50 mM Tris Acetate final concentrations) was dispensed yielding a final reaction volume of 4 ul/well. Luciferase luminescence was measured by a ViewLux plate reader within 5 minutes of enzyme-buffer addition. The % activity was determined by normalizing to the average readings of PTC124 (a positive control) relative to DMSO (0% Activity). The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001640000 uMActivity at 0.0007600859 uMActivity at 0.00164 uMActivity at 0.00357 uMActivity at 0.00764 uMActivity at 0.016 uMActivity at 0.019 uMActivity at 0.041 uMActivity at 0.084 uMActivity at 0.098 uMActivity at 0.204 uMActivity at 0.443 uMActivity at 0.601 uMActivity at 1.020 uMActivity at 2.221 uMActivity at 3.851 uMActivity at 5.200 uMActivity at 11.13 uMActivity at 24.87 uMActivity at 50.60 uMActivity at 58.59 uMActivity at 123.2 uMActivity at 215.3 uMActivity at 288.0 uMCompound QC
Inactive0-4.49220.30.51734-4.606440 0 0 0 0 0 0 01.8042-4.672-4.1025-1.8343-3.7369-2.9082-0.0276-3.27281.8042QC'd by "SIGMA"
Inactive0-4.69224.0450.3458-8.5893-0.540 0 0 0 0 0 0 1-0.1897-6.0169-0.1640.01583.9661-1.6519-0.5167-6.3245-0.1897QC'd by "SigmaAldrich"
Inactive0-5.39224.95490.3662-3.09772.540 0 0 0 0 0 0 15.4199-1.74537.36030.4620.5234.8263-1.6338-2.99815.4199QC'd by "SigmaAldrich"
Inhibitor25.5748105.300940Partial curve; partial efficacy-4.59221.17050.9883-104.96170.3392-2.20 0 0 0 0 0 0 0-79.5165-3.79981.64450.16960.25152.0913-17.2656-49.2902-79.5165QC'd by "SigmaAldrich"
Inactive0-8.74224.44950.68780-6.086140 0 0 0 0 0 0 00.6926-3.82171.16341.2592-1.31090.3214-1.0557-0.36480.6926QC'd by "Chembridge"
Inactive0-4.89224.95490.392-0.6774-5.29640 0 0 0 0 0 0 0-0.8427-4.0002-6.8367-9.83-2.0415-1.9351-6.6372-0.5645-0.8427QC'd by "SigmaAldrich"
Inactive04-1.0545-8.31926.6299-1.3001-1.36740.8591-0.8748-5.7235-1.0545QC'd by "SigmaAldrich"
Inactive0-7.04220.80.711-0.5-4.896140 0 0 0 0 0 0 00.0168-4.0026-5.3301-2.4655-2.99060.3651-2.4180.11760.0168QC'd by "SigmaAldrich"
Inactive0-7.19221.41630.8466-0.5-6.118640 0 0 0 0 0 0 00.8131-6.3489-5.3075-4.1734-1.75011.2452-2.0927-0.96380.8131QC'd by "SigmaAldrich"
Inactive0-4.49224.0950.7889-0.6645-5.329340 0 0 0 0 0 0 0-0.9704-3.9692-5.7573-4.8944-5.7829-4.2413-6.1078-3.7926-0.9704QC'd by "SigmaAldrich"
Inactive0-4.99221.64360.9036-14.27221.540 1 0 0 0 0 0 1-0.79072.64976.5965-1.43033.18260.1904-2.1374-11.4768-0.7907QC'd by "Bosche"
Inactive0-8.69224.95490.89310.5-8.982640 0 0 0 0 0 0 01.1921-6.65221.36940.67421.17880.55330.1933-1.41651.1921QC'd by "SIGMA"
Inactive0-4.54221.64360.921-23.30751.540 0 0 0 0 0 0 0-17.3396-0.19295.88891.776-1.48911.55170.2982-9.8359-17.3396QC'd by "Bosche"
Inactive0-8.29222.47290.43281.5-4.903740 0 0 0 0 0 0 01.6497-4.50310.00170.95285.2306-1.05853.9254-2.26971.6497QC'd by "BIOMOL"
Inactive0-5.24222.40640.7478-1.9233240 0 0 0 0 0 0 0-0.73890.23281.80332.31213.13752.13380.241-2.8528-0.7389QC'd by "SigmaAldrich"
Inactive0-7.79224.95490.6788-3.3068140 0 0 0 0 0 0 14.31810.77691.4337-4.839-0.5865-4.7983-2.6758-3.15854.3181QC'd by "SigmaAldrich"
Inactive041.67591.4738-1.4676-2.88370.649-1.8659-1.6878-2.32581.6759QC'd by "Tocris"
Inactive04-0.47470.1407-1.50182.6348-4.58113.188-1.30740.2134-0.4747QC'd by "SigmaAldrich"
Inactive0-8.04224.95490.45590.3114440 0 0 0 0 0 0 00.54724.15642.6823-3.07390.68322.78941.3999-0.89020.5472QC'd by "SigmaAldrich"
Inactive0-4.39224.95490.91614-3.37340 0 0 0 0 0 0 013.8005-4.4775-3.8406-1.7248-1.4762-1.9012-4.2409-4.071613.8005QC'd by "SigmaAldrich"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.10310.1406-0.03150.12620.060.1031QC'd by "NCI"0
Inactive040.02-0.0462-0.0096-0.0036-0.06880.02QC'd by "NCI"0
Inactive040.0352-0.02430.01330.08820.02270.0352QC'd by "NCI"0
Inactive04-0.0032-0.14120.03560.0067-0.0827-0.0032QC'd by "SigmaAldrich"0
Inactive04-0.0421-6.0E-4-0.01160.00418.0E-4-0.0421QC'd by "NCI"0
Inactive04-0.08870.05490.011900.0103-0.0887QC'd by "NCI"0
Inactive040.05490.14040.09660.0264-0.00150.0549QC'd by "NCI"0
Inactive04-0.0674-0.0024-0.1251-0.0771-0.0044-0.0674QC'd by "NCI"0
Inactive040.07660.11210.11820.1033-0.02320.0766QC'd by "NCI"0
Inactive040.02350.0289-0.01920.0237-0.01010.0235QC'd by "Labotest"0
Inactive04-1.0E-40.04880.0010.01740.0628-1.0E-4QC'd by "NCI"0
Inactive04-0.00820.10220.09650.07640.0317-0.0082QC'd by "NCI"0
Inactive040.04070.1229-0.00830.10480.07010.0407QC'd by "NCI"0
Inactive04-0.0682-0.10260.0427-0.0797-0.01-0.0682QC'd by "NCI"0
Inactive04-0.01790.0067-0.06430.0889-0.0161-0.0179QC'd by "NCI"0
Inactive04-0.0027-0.0933-0.0538-0.0212-0.0192-0.0027QC'd by "NCI"0
Inactive04-0.0156-0.0199-0.013-0.0358-0.0233-0.0156QC'd by "NCI"0
Inactive040.03220.01980.0576-0.00580.03020.0322QC'd by "Chembridge"0
Inactive040.10750.08580.07490.0633-0.01660.1075QC'd by "NCI"0
Inactive04-0.186-0.0569-0.018-0.0052-0.0633-0.186QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a [Homo sapiens]
External ID: AROA258
Protocol: Tox21 Assay Protocol Summary:

MCF-7 aro ERE cells were cultured in assay medium (Phenol red-free MEM containing 10% charcoal stripped FBS) two days prior to the assay. The cells were dispensed at 1,500 cells/4 uL/well into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of Testosterone (0.5 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 24 h. After the plates were incubated at 37C and 5% CO2 for 23.5 h, 1 uL of CellTiter-Fluor reagent (Promega, Madison, WI) of measuring cytotoxicity was added using a Bioraptr FRD workstation. The assay plates were incubated at 37C and 5% CO2 for additional 30 min and the fluorescence intensity was quantified by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo reagent (Promega) was added to each plate using a Bioraptr FRD and luminescence was quantified on a ViewLux (PerkinElmer) plate reader after 30 min incubation at room temperature.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002720541 uM-Replicate_1Activity at 0.0005955401 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.763 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 32.48 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-2.2066-1.1536-4.2174-8.711-6.6426-5.9488-2.0391-15.718-3.7027-4.5545-2.2801-3.7857-12.9599-13.1214-9.6886-2.2066QC'd by SigmaAldrichInactive00.60.524216
Inhibitor4.8311106.123784Complete curve; high efficacy-5.3163.92950.9965-109.1556-3.0318-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-111.611-2.2326-0.9982-2.1761-2.6217-1.2536-0.6776-10.6612-7.1504-2.5933-3.3688-27.6728-95.4648-108.5642-108.8003-111.611QC'd by SigmaAldrichInhibitor9.6393108.044283Complete curve; high efficacy-5.0162.33320.9737-111.3141
Inactive040.5035-0.5614-0.60061.8325-12.3047-7.0616-6.7801-7.5450.0745-7.0388-14.6296-17.129-10.3065-10.04952.84210.5035QC'd by SigmaAldrichInactive00.40.712212
Activator4.786735.1920Complete curve; partial efficacy-5.321.96730.788739.93654.74451.20 0 0 0 0 0 0 0 0 0 0 0 0 0 029.03948.85029.48829.65431.80068.671-15.61197.826913.14394.80715.616715.517731.452742.742446.782229.0394QC'd by SIGMAActivator6.026139.15410Partial curve; partial efficacy-5.220.90.716642.3193
Inactive0413.107-3.69333.8384-3.8759-2.794915.10135.67543.9491-0.481-0.0087-1.35722.7430.4844-0.2286-0.506613.107QC'd by SigmaAldrichInactive0
Inactive00.30.591126140 0 0 0 0 0 0 0 0 0 0 0 0 0 016.5070.22480.16584.54288.20863.07311.62359.30792.96323.47696.953417.436117.45098.245520.704216.507QC'd by SIGMAInactive0
Inactive00.50.6093342.518640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0871-0.04994.374311.83183.87946.24796.7535-0.81793.25538.241615.0466.393516.677312.040126.46280.0871QC'd by SIGMAInactive0
Inactive049.877725.13764.246517.21280.730714.42964.63272.88386.0378.01461.82367.76-0.9897-0.539911.31369.8777QC'd by SIGMAInactive0
Inactive03.1320.3295-2.85236.540 0 0 0 0 0 0 0 0 0 0 0 0 0 114.23829.08182.781819.61592.0565.20476.73762.60575.76535.52163.30952.0753-14.0436-1.25855.163414.2382QC'd by SIGMAInactive00.90.596219
Inactive04-8.817950.49373.29484.0553-0.6701-0.6623-1.2923-7.08623.7302-10.61697.0748-9.6132-5.8222-0.2724-6.1574-8.8179QC'd by SIGMAInactive02.40640.4689-16.5545
Inactive048.37919.77034.99511.86981.2146-1.77476.29237.9265.26814.22540.00622.72662.48328.463714.10848.3791QC'd by SIGMAInactive00.60.514216
Inactive04-8.27240.0281-1.4766-2.28621.25773.831-0.44142.53031.7269-0.7283-1.5332-1.491-14.22041.08090.4188-8.2724QC'd by SigmaAldrichInactive0
Inactive04.95490.3969-6.05574.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.12147.3682.91070.72930.8159.56672.9381-11.3075-8.80042.3752.7959-1.0346-18.7964-0.6442-13.2151-0.1214QC'd by SigmaAldrichInactive0
Inactive041.44823.58520.4997-0.7201-9.4521-0.6989-1.3229-8.92980.74661.0939-11.5869-1.93430.8104-13.6039-1.16031.4482QC'd by SIGMAInactive02.33320.623112.5
Inhibitor60.261387.346841Partial curve; high efficacy-4.223.19250.9468-91.7081-4.3613-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.2637-0.7151-1.4324-8.64940.3488-1.0106-0.8286-10.6048-2.9472-0.5851-2.1641-10.2189-13.2296-5.2897-23.1809-73.2637QC'd by SigmaAldrichInhibitor53.707981.468141Partial curve; high efficacy-4.273.92950.9434-84.2519
Inactive04.95490.5801-7.1836-0.829740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.1223-1.2322-1.1081-1.7584-8.8414-5.325-10.4209-6.1753-4.2522-4.2314-10.9863-7.5165-5.1054-7.8585-8.4654-9.1223QC'd by ChemServiceInactive04.95490.35784.5
Inhibitor24.3613103.983841Partial curve; high efficacy-4.61332.35310.9238-97.82326.1605-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.92071.595-3.3685-2.9295-0.3657-0.674810.0521.01462.20929.916924.275426.29-4.4212-30.9132-70.0689-96.9207QC'd by SIGMAInhibitor27.3338108.053740Partial curve; high efficacy-4.56331.98870.9107-103.8107
Inactive04-1.8107-0.19851.1239-2.7571-9.5761-2.0759-8.4016-9.53090.2125-1.6114-8.3569-1.504-7.968-1.193-6.8529-1.8107QC'd by SigmaAldrichActivator42.969237.94450Partial curve; partial efficacy-4.36682.72020.911335.5
Inactive04-0.8051-6.3306-0.3852-7.0596-0.1656-3.4084-6.7899-11.8797-7.7193-10.2069-7.5291-14.8365-8.1408-1.5169-2.1071-0.8051QC'd by SigmaAldrichActivator0.436315.75320Complete curve; partial efficacy; poor fit-6.36024.95490.518712.5053
Inactive04-0.53480.5678-2.8997-2.84370.38943.491-6.100814.436-0.80381.870613.74841.2268-0.08231.5329-0.0037-0.5348QC'd by SigmaAldrichInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.06820.17150.15520.2805-0.08310.0682QC'd by "APAC"0
Inactive040.0073-0.03930.005-0.09740.03070.0073QC'd by "APAC"0
Inactive04-0.4123-0.248-0.1541-0.1037-0.0973-0.4123QC'd by "APAC"0
Inactive040.19330.41050.28830.44640.38910.1933QC'd by "APAC"0
Inactive040.44160.65360.7260.63220.73960.4416QC'd by "APAC"0
Inactive040.2127-0.00470.08240.2587-0.01090.2127QC'd by "APAC"0
Inactive040.13480.40170.15030.02750.21030.1348QC'd by "APAC"0
Inactive040.16380.07840.19640.35280.10370.1638QC'd by "APAC"0
Inactive04-0.0775-0.1328-0.144-0.2205-0.105-0.0775QC'd by "APAC"0
Inactive040.12810.06390.0321-0.01010.04060.1281QC'd by "APAC"0
Inactive04-0.4235-0.3306-0.3534-0.2876-0.4525-0.4235QC'd by "APAC"0
Inactive040.1880.24950.21320.11330.30530.188QC'd by "APAC"0
Inactive040.26490.13370.33710.1823-0.01240.2649QC'd by "APAC"0
Inactive040.14720.44310.35470.41120.45620.1472QC'd by "APAC"0
Inactive040.18370.1140.0230.16450.38450.1837QC'd by "APAC"0
Inactive04-0.5082-0.4883-0.5711-0.5038-0.4992-0.5082QC'd by "APAC"0
Inactive04-0.2494-0.1585-0.0187-0.265-0.2494-0.2494QC'd by "APAC"0
Inactive04-0.489-0.6545-0.2063-0.2875-0.5573-0.489QC'd by "APAC"0
Inactive04-0.1512-0.1725-0.2697-0.1595-0.2932-0.1512QC'd by "APAC"0
Inactive040.1730.29550.30070.26150.34070.173QC'd by "APAC"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53
External ID: P53823
Protocol: Please refer to other AIDs, 651631 and 651633, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the P53 assay (AID 651631) and cell viability counter screen (AID 651633). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0inconclusive agonist15.55089081inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusive agonistinconclusive agonist18.58791134inactive0active agonist29.8492948138.73741641inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusiveactive agonist28.7254875625.5057883active antagonist29.84929481-51.18360188inactive0active antagonist29.84929481-98.84256078SigmaAldrich
inconclusiveinconclusive agonist14.35525499inconclusive antagonist31.61797672-26.09239449inactive0active antagonist26.603212-72.63099375NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inconclusive antagonistLabotest
inconclusiveactive agonist33.4914596364.83524463active antagonist33.49145963-59.84708639inactive0inconclusive antagonist28.17955142-95.15844265NCI
inconclusive agonistinconclusive agonist10.75907896inactive0active agonist19.07705083inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusiveinconclusive agonist33.4914596379.63843875inconclusive antagonist31.61797672-53.76954664inactive0active antagonist29.84929481-106.2599059NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0Chembridge
inactiveinactive0inactive0inactive0inactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0303-0.04260.0285-0.09190.0085-0.0303QC'd by "NCI"0
Inactive040.0853-0.06580.02019.0E-40.06280.0853QC'd by "NCI"0
Inactive040.16730.04180.01560.0204-0.00980.1673QC'd by "NCI"0
Inactive04-0.1980.02190.0160.02350.0689-0.198QC'd by "SigmaAldrich"0
Inactive040.0038-0.0014-0.00825.0E-4-0.1170.0038QC'd by "NCI"0
Inactive040.0026-0.0041-0.01760.0697-0.01480.0026QC'd by "NCI"0
Inactive040.1333-0.0845-0.0206-0.01310.12030.1333QC'd by "NCI"0
Inactive040.03690.00440.0618-0.01070.01570.0369QC'd by "NCI"0
Inactive04-0.02150.02550.01530.1030.0492-0.0215QC'd by "NCI"0
Inactive04-0.00280.08780.0034-0.01623.0E-4-0.0028QC'd by "Labotest"0
Inactive040.02210.0083-0.0285-0.04060.10790.0221QC'd by "NCI"0
Inactive040.02430.10020.08470.0514-0.00220.0243QC'd by "NCI"0
Inactive040.00680.024-0.00130.0328-0.11050.0068QC'd by "NCI"0
Inactive040.03090.0251-0.2255-0.1044-0.07930.0309QC'd by "NCI"0
Inactive04-0.0428-0.0779-0.07410.0110.0229-0.0428QC'd by "NCI"0
Inactive040.07660.0357-0.02130.0861-0.01260.0766QC'd by "NCI"0
Inactive04-0.0349-0.0548-0.0746-0.0452-0.1742-0.0349QC'd by "NCI"0
Inactive040.15650.01040.0178-0.0320.02410.1565QC'd by "Chembridge"0
Inactive04-0.05070.0691-0.01840.01950.0897-0.0507QC'd by "NCI"0
Inactive04-0.0232-0.1816-0.1161-0.2126-0.2187-0.0232QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.060.0769-0.0561-0.05340.0765-0.06QC'd by "NCI"0
Inactive04-0.02860.01850.15430.03970.0134-0.0286QC'd by "NCI"0
Inactive041.25510.11730.01450.07070.51551.2551QC'd by "NCI"0
Inactive040.0380.0229-0.1395-0.01880.42040.038QC'd by "SigmaAldrich"0
Inactive041.3250.07660.1836-0.10240.07711.325QC'd by "NCI"0
Inactive040.1088-0.12430.0941-0.0246-0.04550.1088QC'd by "NCI"0
Inactive040.00260.0529-0.1116-0.1678-0.11720.0026QC'd by "NCI"0
Inactive040.17340.0511-0.06420.11-0.13760.1734QC'd by "NCI"0
Inactive040.0031-0.0257-0.0731-0.021-0.01490.0031QC'd by "NCI"0
Inactive04.0950.98722.5040 0 0 0 02.51080.00570.26280.01340.77542.5108QC'd by "Labotest"0
Inactive04-0.05950.0115-0.03130.04540.0652-0.0595QC'd by "NCI"0
Inactive040.7551-0.0030.0690.14220.06940.7551QC'd by "NCI"0
Inactive04-0.0762-0.099-0.14750.0756-0.1338-0.0762QC'd by "NCI"0
Inactive040.0533-0.1182-0.00850.0808-0.08810.0533QC'd by "NCI"0
Inactive041.4117-0.0519-0.0295-0.05670.23241.4117QC'd by "NCI"0
Inactive040.15250.02280.10290.03280.11910.1525QC'd by "NCI"0
Inactive040.97520.1286-0.0289-0.0041-0.01590.9752QC'd by "NCI"0
Inactive040.090.11160.0522-0.0224-0.17680.09QC'd by "Chembridge"0
Inactive040.12760.09120.04220.0790.08710.1276QC'd by "NCI"0
Inactive04-0.05040.00170.0374-0.2014-0.0226-0.0504QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0468-1.0E-4-0.0634-0.0128-0.1309-0.0468QC'd by "NCI"0
Inactive04-0.02170.0466-0.04120.00330.0551-0.0217QC'd by "NCI"0
Inactive04-0.0248-0.00450.0622-0.03730.0284-0.0248QC'd by "NCI"0
Inactive040.01860.0540.055-7.0E-40.08120.0186QC'd by "SigmaAldrich"0
Inactive040.02420.07270.1578-0.01480.02860.0242QC'd by "NCI"0
Inactive040.08870.03620.13790.04160.03120.0887QC'd by "NCI"0
Inactive040.10310.0424-0.0028-0.06470.0120.1031QC'd by "NCI"0
Inactive040.022-0.01990.0104-0.01420.03070.022QC'd by "NCI"0
Inactive040.58190.1190.05910.03290.05860.5819QC'd by "NCI"0
Inactive04-0.01230.04580.0457-0.03880.0399-0.0123QC'd by "Labotest"0
Inactive04-0.0094-0.02560.0289-0.00760-0.0094QC'd by "NCI"0
Inactive040.11950.07450.00670.004-0.05970.1195QC'd by "NCI"0
Inactive04-0.0059-0.05640.01470.0049-0.0156-0.0059QC'd by "NCI"0
Inactive04-0.05470.0295-0.0247-0.0665-0.0356-0.0547QC'd by "NCI"0
Inactive04-0.0413-0.0059-0.1195-0.0027-0.0175-0.0413QC'd by "NCI"0
Inactive040.175-0.00450.11290.06590.06270.175QC'd by "NCI"0
Inactive04-0.0317-0.0316-0.01050.0141-0.0074-0.0317QC'd by "NCI"0
Inactive040.06210.0243-0.0520.16910.01120.0621QC'd by "Chembridge"0
Inactive040.0158-0.02480.0493-0.0242-0.02880.0158QC'd by "NCI"0
Inactive04-0.0654-0.1331-0.0734-0.03930.0109-0.0654QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.2003-0.01150.00710.23730.09540.2003QC'd by "NCI"0
Inactive040.1113-0.03910.08984.0E-4-0.03890.1113QC'd by "NCI"0
Inactive04-0.09730.0277-0.0084-0.00980.0055-0.0973QC'd by "NCI"0
Inactive04-0.1827-0.0289-0.0224-0.1537-0.0181-0.1827QC'd by "SigmaAldrich"0
Inactive040.5452-0.03350.0032-0.01370.01630.5452QC'd by "NCI"0
Inactive04-0.05130.011-0.0106-0.0503-0.0065-0.0513QC'd by "NCI"0
Inactive04-0.0252-0.1196-0.0502-0.05650.0376-0.0252QC'd by "NCI"0
Inactive040.10450.0373-0.01590.03940.00210.1045QC'd by "NCI"0
Inactive04-0.24220.0063-0.0071-0.0119-0.0133-0.2422QC'd by "NCI"0
Inactive04.50450.98673040 0 0 0 03.1340.15520.13580.19860.6053.134QC'd by "Labotest"0
Inactive04-0.0090.01850.03930.2310.0436-0.009QC'd by "NCI"0
Inactive040.07510.02710.22620.17550.01740.0751QC'd by "NCI"0
Inactive040.0132-0.0598-0.0350.09430.07230.0132QC'd by "NCI"0
Inactive049.0E-4-0.0911-0.05740.15930.17099.0E-4QC'd by "NCI"0
Inactive040.6834-0.1194-0.00280.3720.19860.6834QC'd by "NCI"0
Inactive040.1104-0.08290.06180.16230.0230.1104QC'd by "NCI"0
Inactive040.5456-0.0786-0.0186-0.0058-0.00230.5456QC'd by "NCI"0
Inactive04-0.1424-0.0976-0.10020.027-0.1146-0.1424QC'd by "Chembridge"0
Inactive040.0252-0.0593-0.08240.12910.04990.0252QC'd by "NCI"0
Inactive040.0384-0.2038-0.1551-0.007-0.01920.0384QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.12420.2628-0.1782-0.4447-0.2156-0.1242QC'd by "NCI"0
Inactive040.52820.2696-0.353-0.2319-0.17610.5282QC'd by "NCI"0
Inactive040.36990.109-0.00360.2172-0.0050.3699QC'd by "NCI"0
Inactive040.003-0.1398-0.2166-0.05930.03410.003QC'd by "SigmaAldrich"0
Inactive040.0037-0.18840.15210.18170.12320.0037QC'd by "NCI"0
Inactive040.42260.0606-0.0267-0.1598-0.03750.4226QC'd by "NCI"0
Inactive04-0.1083-0.0289-0.054-0.2945-0.072-0.1083QC'd by "NCI"0
Inactive04-0.0618-0.03660.04-0.2576-0.1156-0.0618QC'd by "NCI"0
Inactive040.0450.2884-0.027-0.166-0.30740.045QC'd by "NCI"0
Inactive04-0.2251-0.37-0.4364-0.0983-0.1209-0.2251QC'd by "Labotest"0
Inactive04-0.32420.23140.0134-0.2318-0.0596-0.3242QC'd by "NCI"0
Inactive04-0.01610.01530.03390.01490.0696-0.0161QC'd by "NCI"0
Inactive04-0.00830.0949-0.2516-0.1363-0.3201-0.0083QC'd by "NCI"0
Inactive040.1281-0.3790.11360.0866-0.02890.1281QC'd by "NCI"0
Inactive04-0.0989-0.0902-0.1041-0.2289-0.1987-0.0989QC'd by "NCI"0
Inactive040.0739-0.0110.01860.02430.02880.0739QC'd by "NCI"0
Inactive04-0.20280.08760.015-0.0122-0.012-0.2028QC'd by "NCI"0
Inactive04-0.152-0.0722-0.03940.08260.0334-0.152QC'd by "Chembridge"0
Inactive04-0.0720.1489-0.00810.015-0.0036-0.072QC'd by "NCI"0
Inactive04-0.1159-0.19220.11950.16620.2987-0.1159QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11908 靶标:N/A
External ID: RMI-FANCM-MM2
Protocol: FP HTS. Screening took place at the University of Wisconsin Small Molecule Screening and Synthesis Facility. A master mix of RMI core complex and F-MM2 (30 microL per well) was plated in black 384 shallow well plates (ThermoFisher, Waltham, MA), using a BioTek "MicroFlo Select" reagent dispenser. Compounds were added using a Beckman FX liquid handler; 0.33 microL of 10 mM stock was added for a final compound concentration of 33 microM. MM2 and cMM2 were each added to 4 wells of master mix per plate to a final concentration of 10 muM to serve as controls. Following compound addition, plates were covered, centrifuged briefly, and incubated for 20 minutes at room temperature. FP measurements were taking using a Tecan "Safire 2" microplate reader. Instrument settings were as follows: top read, EX 470, EM 525/20, G-factor 0.89947. A suitable gain was calculated from the first plate of each day. Z' scores for were calculated for each plate; plates with Z' scores <0.5 were rerun prior to analysis.
Comment:
Concentration uMData readout
3355
3363
3365
3363
3361
3362
3361
3358
3371
3361
3364
3383
33158
3384
33104
3360
3362
3359
3358
3359
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1115-0.1251-0.0765-0.06640.0949-0.1115QC'd by "SIGMA"0
Inactive04-0.0069-0.10850.02610.0208-0.0462-0.0069QC'd by "SigmaAldrich"0
Inactive04-0.172-0.0309-0.0124-0.0718-0.0262-0.172QC'd by "SIGMA"0
Inactive040.0130.0073-0.01730.01340.00240.013QC'd by "SigmaAldrich"0
Inactive04-0.052-0.0612-0.0736-0.0496-0.0413-0.052QC'd by "SigmaAldrich"0
Inactive04-0.0569-0.01650.10050.1139-0.0959-0.0569QC'd by "SigmaAldrich"0
Inactive04-0.0353-0.0623-0.04670.00960.0134-0.0353QC'd by "SIGMA"0
Inactive040.22820.00980.01520.0163-0.02330.2282QC'd by "Alfa Aesar"0
Inactive04-0.1287-0.0353-0.0866-0.012-0.0014-0.1287QC'd by "SIGMA"0
Inactive04-0.0565-0.1141-0.0255-0.009-0.0415-0.0565QC'd by "SIGMA"Inactive04
Inactive04-0.1244-0.1158-0.0769-0.0272-0.0887-0.1244QC'd by "SIGMA"0
Inactive04-0.1459-0.077-0.0696-0.0992-0.1072-0.1459QC'd by "SIGMA"0
Inactive04-0.0112-0.12120.0729-0.0657-0.1082-0.0112QC'd by "SIGMA"0
Inactive04-0.0758-0.1319-0.0931-0.0564-0.0431-0.0758QC'd by "SIGMA"0
Inactive04-0.0061-0.0301-0.0049-0.0052-0.0205-0.0061QC'd by "SigmaAldrich"0
Inactive040.06630.0020.1992-0.0417-0.05850.0663QC'd by "SigmaAldrich"0
Inactive040.1620.0128-0.0595-0.0493-0.05030.162QC'd by "Interchem"0
Inactive04-0.0217-0.0781-0.08430.00810.004-0.0217QC'd by "SigmaAldrich"0
Inactive040-0.0307-1.0E-4-0.0089-0.03580QC'd by "SigmaAldrich"0
Inactive04-0.02990.0039-0.03650.0192-0.0786-0.0299QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: AROV112
Protocol: Tox21 Assay Protocol Summary:

MCF-7 aro ERE cells were cultured in assay medium (Phenol red-free MEM containing 10% charcoal stripped FBS) two days prior to the assay. The cells were dispensed at 1,500 cells/4 uL/well into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of Testosterone (0.5 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 24 h. After the plates were incubated at 37C and 5% CO2 for 23.5 h, 1 uL of CellTiter-Fluor reagent (Promega, Madison, WI) of measuring cytotoxicity was added using a Bioraptr FRD workstation. The assay plates were incubated at 37C and 5% CO2 for additional 30 min and the fluorescence intensity was quantified by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002720541 uM-Replicate_1Activity at 0.0005955401 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00613 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.342 uM-Replicate_1Activity at 0.763 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 32.48 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0413.0889-1.66864.478718.6854-0.48264.7953-0.59428.07730.92478.9629-2.196715.345715.139216.4786.722113.0889QC'd by NCIInactive0
Cytotoxic13.333236.732221Complete curve; partial efficacy-4.87514.95490.7923-29.6627.0702-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14381.479820.25985.08754.60124.75079.9862-3.20264.47916.0258-0.530311.199220.09346.1387-29.52-31.1438QC'd by NCICytotoxic21.1317103.350741Partial curve; high efficacy-4.67511.86170.9757-102.1811
Inactive040.4471-2.8001-1.7403-1.12262.98012.11316.665210.218212.80795.8803-0.2215-10.6114-1.02321.931912.73780.4471QC'd by NCIInactive0
Cytotoxic29.849391.037120Single point of activity-4.52514.95490.971-90.40840.6287-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.49860.17360.6935-1.3312-0.206112.2146-4.40990.0668-1.3756-0.3616-1.11661.2081-0.25880.0225-8.4892-81.4986QC'd by SigmaAldrichCytotoxic29.849396.057440Partial curve; high efficacy-4.52514.0950.9745-98.4887
Cytotoxic29.849343.259620Partial curve; partial efficacy; poor fit-4.52512.58840.654-43.934-0.6743-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.54971.51315.83030.6388-4.89485.5838-6.034-5.42513.19371.27950.2248-7.0642-13.9432-0.3387-11.983-33.5497QC'd by NCICytotoxic23.710154.80320Partial curve; partial efficacy-4.62513.06540.9118-56.0531
Inactive03.990.463312-3.545940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.1224-1.1431-0.4077-9.2962-6.7439-1.3041-5.108-0.428-0.48521.6732-2.7718-12.1216-1.7511-0.57919.852-5.1224QC'd by NCIInactive0
Inactive048.2451-2.30262.27657.3956-4.68135.92238.448911.15386.86045.9576.8113.9931-7.5923-6.506313.20258.2451QC'd by NCIInactive0
Inactive047.8779-11.401-0.64871.58362.34767.156-6.7357-11.41271.6491-7.1693-11.7901-8.769-6.8463-0.06161.77097.8779QC'd by NCIInactive04.95490.57718
Cytotoxic29.849357.823420Single point of activity-4.52514.95490.8931-57.47810.3453-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.2317-1.15572.6188-7.7075-0.359.48620.1230.66930.6672-2.0531-1.7983-5.341910.3150.1178-7.6014-51.2317QC'd by NCICytotoxic26.603247.886120Partial curve; partial efficacy-4.57513.1320.946-50.222
Inactive04-2.258415.0081.8981-5.02357.271710.479510.62950.407-2.5232-2.4835-0.74710.0879-1.3303-2.762810.6838-2.2584QC'd by LabotestInactive0
Inactive04.44950.4193-2.29222.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.9246-0.8801-0.53812.6488-0.05617.27753.7735.28930.09192.13935.6234-1.8779-4.8269-1.53031.2059-3.9246QC'd by NCIInactive03.92950.6224-26.8855
Inactive044.84140.39352.1814-15.55856.1583-2.7506-1.29682.408-3.1984-19.027510.67640.856914.6462-2.9317-22.00254.8414QC'd by NCIInactive0
Inactive04-3.117-2.9332-1.54190.48350.1637-4.1579-1.392-1.1741-1.09652.2022-5.70182.53112.8257-1.2786-0.6983-3.117QC'd by NCIInactive0
Cytotoxic29.849370.737440Partial curve; high efficacy-4.52514.95490.9648-74.0453-3.3079-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-66.7044-0.8515-0.6476-6.75680.34160.33811.3744-2.6166-7.5972-0.9959-6.0997-2.5425-6.0215-8.4358-12.6041-66.7044QC'd by NCICytotoxic29.849394.666240Partial curve; high efficacy-4.52514.95490.9892-97.0028
Inactive01.10.33837-5.697440 0 0 0 0 0 0 0 0 0 0 0 0 0 07.3431-6.3907-4.9726-7.29748.7208-13.9145-5.2667-5.7344-12.4941-5.56985.73531.1859-7.230414.63531.82357.3431QC'd by NCIInactive00.90.589217
Inactive045.737312.5288-1.0974-2.79388.27274.0907-1.41678.99574.80517.5768-1.30747.23573.08392.88293.96365.7373QC'd by NCIInactive03.19250.4553-4.6844
Inactive044.5023.9295-8.0465-3.62329.46645.37291.138612.185-3.65222.981114.46385.46410.06047.6392-5.06044.502QC'd by NCIInactive0
Inactive04-1.9982-3.6344-4.6559-0.3788-2.1166-1.2585-1.98810.0232-0.9085-1.1425-5.0225-1.24591.0659-5.4568-3.298-1.9982QC'd by ChembridgeInconclusive26.603228.322310Partial curve; partial efficacy; poor fit-4.57512.09370.871525.5
Inactive04-16.5603-2.74410.3192.3141-0.1723-19.45910.0669-17.7681-2.4009-3.26419.5003-3.13731.90082.00541.7817-16.5603QC'd by NCICytotoxic33.491536.815220Partial curve; partial efficacy; poor fit-4.47514.95490.7907-33.8152
Inactive04-9.10111.67360.31128.9066.348410.2071-6.926413.5429-4.395717.17929.543-14.114110.7621-0.2142-14.2769-9.1011QC'd by NCIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.77120.05930.0635-0.0984-0.218-0.7712QC'd by "Prestwick Chemical; Inc."0
Inactive040.28480.45950.13770.23990.45920.2848QC'd by "Prestwick Chemical; Inc."0
Inactive040.10910.08720.002-0.128-0.01040.1091QC'd by "Prestwick Chemical; Inc."0
Inactive040.35690.44360.30790.14920.38140.3569QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4718-0.21590.1141-0.2538-0.4782-0.4718QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.7519-0.0052-0.0382-0.3499-0.5531-0.7519QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3026-0.176-0.2919-0.2217-0.1667-0.3026QC'd by "Prestwick Chemical; Inc."0
Inactive040.00260.10340.01420.20370.21520.0026QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.309-0.54610.3903-0.3625-0.0293-0.309QC'd by "Prestwick Chemical; Inc."0
Inactive040.1015-0.23980.08980.41030.37930.1015QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.02650.19180.1501-0.07350.0724-0.0265QC'd by "Prestwick Chemical; Inc."0
Inactive040.3519-0.54170.1370.20740.37870.3519QC'd by "Prestwick Chemical; Inc."0
Inactive040.11140.07490.32080.3560.48040.1114QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.45320.0227-0.0204-0.4367-0.3391-0.4532QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4937-0.7632-0.0181-0.4913-0.1598-0.4937QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.2868-0.3361-0.3349-0.465-0.3474-0.2868QC'd by "Prestwick Chemical; Inc."0
Inactive040.33880.03910.14580.56180.08170.3388QC'd by "Prestwick Chemical; Inc."0
Inactive040.5747-0.55850.02420.36260.57350.5747QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3048-0.2054-0.3202-0.3697-0.1434-0.3048QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.27210.25420.1392-0.3556-0.4304-0.2721QC'd by "Prestwick Chemical; Inc."0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0029-0.0082-0.00260.13990.0699-0.0029QC'd by "SIGMA"0
Inactive04-0.10090.004-0.1385-0.05520.0167-0.1009QC'd by "ChromaDex"0
Inactive04-0.00270.04690.0106-0.0323-0.0264-0.0027QC'd by "SIGMA"0
Inactive040.0680.04520.00930.1349-0.05650.068QC'd by "SigmaAldrich"0
Inactive04-0.01020.00830.0497-0.0368-0.1188-0.0102QC'd by "Sensient"0
Inactive040.16110.01260.0217-0.06560.10580.1611QC'd by "Pfaltz-Bauer"0
Inactive040.01860.00820.0242-0.11250.1760.0186QC'd by "SigmaAldrich"0
Inactive040.0141-0.0188-0.03030.00210.09840.0141QC'd by "SigmaAldrich"0
Inactive04-0.06960.0137-0.0094-0.0575-0.0122-0.0696QC'd by "SigmaAldrich"0
Inactive04-0.0879-0.00670.1326-0.0156-0.0041-0.0879QC'd by "SigmaAldrich"0
Inactive040.0162-0.0159-0.0079-0.01810.08710.0162QC'd by "SigmaAldrich"0
Inactive040.02930.0807-0.0391-0.1788-0.09160.0293QC'd by "SIGMA"0
Inactive04-0.0528-0.0224-0.08430.0049-0.0082-0.0528QC'd by "SIGMA"0
Inactive040.11520.05240.1778-0.0592-0.05560.1152QC'd by "SIGMA"0
Inactive04-0.03240.04210.01430.01780.0302-0.0324QC'd by "SIGMA"0
Inactive04-0.1527-0.0095-0.1287-0.0855-0.0912-0.1527QC'd by "SIGMA"0
Inactive040.1560.0209-0.00190.010.00660.156QC'd by "SIGMA"0
Inactive040.0052-0.00170.0141-0.07196.0E-40.0052QC'd by "SIGMA"0
Inactive04-0.0288-0.0779-0.0066-0.0587-0.0039-0.0288QC'd by "SIGMA"0
Inactive04-0.0014-0.08470.0444-0.017-0.0041-0.0014QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:peripheral myelin protein 22 [Rattus norvegicus]
External ID: cmt-p4-fluc-fda_regid
Protocol: S16 Schwann cell PMP22 intronic element firefly luciferase assay
The FLuc-expressing S16 cells were seeded in white solid 1536-well plates at between 500-750 cells/4uL in DMEM medium containing 10% FBS, w/o phenol red. After overnight incubation at 37 degree Celsius/5% C02, 23 nL of compounds or DMSO were delivered to each well using a pin tool, followed by 24h-incubation at 37 degree Celsius/5% C02. Then 4 uL ONE-Glo luminescent substrate mix (Promega) was added to each well. Luminescence was measured on a ViewLux plate reader (Perkin Elmer). The % activity was determined by normalizing to the average readings of PTC124 (a positive control) - treated cells relative to DMSO-treated cells (0% Activity). The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001640000 uMActivity at 0.0007350000 uMActivity at 0.0008220000 uMActivity at 0.00164 uMActivity at 0.00382 uMActivity at 0.00822 uMActivity at 0.019 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.206 uMActivity at 0.477 uMActivity at 1.030 uMActivity at 2.387 uMActivity at 5.336 uMActivity at 11.50 uMActivity at 25.70 uMActivity at 57.50 uMCompound QC
Inactive047.72030.8659-2.631626.4627-3.5335.70055.6162-6.89097.7203QC'd by "Chemical Block"
Inactive0-8.09223.51170.3502-0.7805840 0 0 0 0 0 0 03.2147.70063.7655-1.8745-5.09147.2979-5.6504-1.19463.214QC'd by "NIEHS"
Activator0.5725145.54280Complete curve; high efficacy-6.24221.28760.9301135.9892-9.55361.10 0 0 0 0 0 0 116.8036-10.54143.5227-23.509434.648176.9926154.1828115.554416.8036QC'd by "Bionet"
Inactive0-6.94224.95490.8667-7.52921840 0 0 0 0 0 0 0-3.302417.306414.585221.5063-6.9554-17.5244-6.2651-1.7153-3.3024QC'd by "Microsource"
Inactive0-6.49220.90.61392.531618.540 0 0 0 0 0 0 05.163916.209519.972615.599416.4813-1.223712.1710.96565.1639QC'd by "SigmaAldrich"
Inhibitor11.423977.212162Complete curve; partial efficacy-4.94224.95490.9484-72.37674.8355-1.20 0 0 0 0 0 0 0-66.34033.8942-8.8439-0.499916.45268.36299.8573-76.8381-66.3403QC'd by "BIOMOL"
Inactive0-7.99224.95490.727413-6.972340 0 0 0 0 0 0 015.738-7.0603-1.393621.18974.47710.39715.28359.863915.738QC'd by "BIOMOL"
Inactive0-4.39224.95490.6125-10.695812.540 0 0 0 0 0 0 0-8.91328.44036.171423.02966.129917.144711.573813.1002-8.9132QC'd by "Microsource"
Inactive04-4.4526-4.0128-7.78831.7483-10.2179-16.325-24.6675-1.5165-4.4526QC'd by "SigmaAldrich"
Inhibitor16.1366111.356610Single point of activity-4.79224.95490.9134-102.9858.3716-30 0 0 0 0 0 0 1-16.77037.232426.7976-2.6004-8.50019.385517.0307-92.7972-16.7703QC'd by "BIOMOL"
Inhibitor16.136681.614141Partial curve; partial efficacy-4.79221.62590.9436-75.61416-2.20 0 0 0 0 0 0 0-70.28398.929516.981-8.24474.56678.2089-8.3819-47.4244-70.2839QC'd by "Microsource"
Inactive0-5.59224.44950.4256-9.885311.719640 0 0 0 0 0 0 0-9.071112.78140.95115.70613.5586.626932.0270.4458-9.0711QC'd by "BIOMOL"
Activator0.057321.59260Complete curve; partial efficacy; poor fit-7.24224.95490.832221.5-0.09261.40 0 0 0 0 0 0 1-1.22431.1667-1.32724.134230.183219.819121.766513.8201-1.2243QC'd by "BIOMOL"
Inhibitor18.105652.280721Partial curve; partial efficacy-4.74223.67720.9826-47.78074.5-2.20 0 0 0 0 0 0 0-49.93183.8651.646410.75552.55154.53663.2482-35.6751-49.9318QC'd by "BIOMOL"
Inhibitor22.793673.383320Partial curve; partial efficacy-4.64221.85790.9044-52.409520.9738-2.20 0 0 0 0 0 0 0-41.328131.830419.621231.110913.02038.637315.6851-19.835-41.3281QC'd by "SigmaAldrich"
Activator40.533444.51110Single point of activity-4.39224.95490.643848.54214.030931 0 0 0 0 0 0 045.288229.66648.6048.8809-7.159525.2792.32966.138745.2882QC'd by "SigmaAldrich"
Activator40.533444.63340Single point of activity-4.39224.95490.731647.11612.482730 0 0 0 0 0 0 046.30267.4755-0.75819.27525.209310.4838-1.83621.18346.3026QC'd by "BIOMOL"
Inactive04-0.5052-7.6408-15.7325-0.3027-1.2325-21.3639-9.9587-7.7655-0.5052QC'd by "BIOMOL"
Inactive04-12.3719-13.0834-12.0648-10.9788-16.5816-4.45632.3382-18.163-12.3719QC'd by "NIEHS"
Inhibitor28.695494.188640Partial curve; high efficacy-4.54223.990.9769-86.68867.5-2.10 0 0 0 0 0 0 0-81.40725.66564.976614.47514.160.761214.9064-28.9281-81.4072QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: HERG01
Protocol: NCGC Assay Protocol Summary:

HERG assay (FluxORTM thallium flux assay) was initially developed by Invitrogen/Molecular Probes, and then miniaturized into 1536-well plate in a homogeneous format by NCGC. This assay measures the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells with a FDSS-7000 kinetic plate reader (Hamamatsu Corp., Hamamatsu City, Japan). The hERG ion channel is transduced into mammalian cells (U2OS) using a baculovirus (Bacmam) construct harboring the hERG K+ ion channel. So far we screened LOPAC1280 library (Sigma), the NTP collection of 1408 compounds, and the NCGC Pharmaceutical Collection (NPC), in which many well defined HERG blockers are present. The rank order potencies of many of these compounds are similar to that of other HERG assays (membrane potential, Rb+ flux, patch clamp, etc). This quick and homogeneous assay is also found to be sensitive, specific, and robust.

Using the FluxORTM thallium flux assay, the activity of potassium channel using thallium dye (FluxOR) flux as surrogate measurement for potassium into the cells was measured in the U2OS cell line transduced with hERG K+ ion channel using a baculovirus (Bacmam) using Opti-MEM medium (Invitrogen) containing 2% fetal calf serum (FCS, HyCone) following loading buffer addition, compound treatment for around 10 minutes and finally adding stimulation buffer. The assay was performed in black clear Kalypsys 1536-well plates. In the screen, Astemizole was used as positive controls. Library compounds were measured for their ability to cause hERG channel blockage in the cell line, as reflected by a decrease in fluorescence intensity, in a concentration-dependent manner. Data were normalized to the controls for basal activity (DMSO only) and 100% inhibition (5uM Astemizole). AC50 values were determined from concentration-response data modeled with the standard Hill equation.

qHTS protocol for hERG-U2OS cellular assay

[Step] [Parameter] [Value] [Description]

1. Day 1: Replace medium in 70-80% confluent T225 flask with 2.5 mL of hERG-BacMam virus plus 12.5 mL of phosphate buffered saline (PBS) (corresponding roughly to a multiplicity of infection ratio of 100 virus particles/cell)
2. Incubation: 4 hrs @ room Temperature in Dark
3. Reagent; Remove virus; wash once with 25 ml DPBS
4. Reagent; 35 ml culture medium
5. Incubation; 37oC overnight
6. Day2: Reagent; 3 uL; 2000 U2OS cells/well
7. Time; 4 hr; 37oC incubation
8. Loading buffer; 1 uL; 0.7X;
9. Incubation: 1hr @ RT in Dark.
10. Compounds; 23 nL; 0.59 nM to 92 uM
11. Controls; 23 nL; Astemizole 1.4 nM to 92 uM
12. Time; 10min; 37oC incubation
13. Read fluorescence Intensity on FDSS for 10 Sec with 1 sec interval
14. Reagent; 1 uL; stimulation buffer
15. Read fluorescence Intensity on FDSS for 2 min with 1 sec interval
16. Detection; Fluorescence Intensity; FDSS
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0001000000 uMActivity at 0.0003000000 uMActivity at 0.0006116734 uMActivity at 0.00133 uMActivity at 0.00297 uMActivity at 0.00673 uMActivity at 0.015 uMActivity at 0.033 uMActivity at 0.075 uMActivity at 0.167 uMActivity at 0.369 uMActivity at 0.412 uMActivity at 0.836 uMActivity at 1.842 uMActivity at 2.061 uMActivity at 4.179 uMActivity at 9.216 uMActivity at 20.61 uMActivity at 46.08 uMActivity at 92.17 uMCompound QC
Inactive04.0950.5622-0.5-17.405541 0 0 0 0 0 1 0 0 0 0 0 0 04.0358-8.1088-16.5879-0.7265-5.65844.3730.1327-9.70320.36854.1527-0.141-3.5272-0.9713-9.32034.0358QC'd by NIEHS/NTP
Activator15.848952.39750Single point of activity-4.80.40.510848.9806-3.416930 0 0 0 0 1 0 0 0 0 0 1 0 1 038.06212.0116-8.9739-7.06230-7.0944-39.2396018.733825.780800-59.539411.623748.215338.0621QC'd by NIEHS
Inactive04-1.0832-10.89741.0031-11.058-11.8883.65680.91825.31740.029-1.48932.17113.0788-19.8367-2.8584-1.0832QC'd by NIEHS/NTP
Inactive042.45982.223-1.63678.778-0.11389.22693.440711.6742-2.146511.8823-1.8078-2.0833.78254.49092.4598QC'd by NIEHS
Inactive01.85790.45754.5-21.089940 0 0 0 0 0 0 0 0 0 0 0 0 012.886-15.90830.10180.3771-0.02467.9993-3.79713.097311.63728.3022-2.66639.3202-2.3421-0.285412.886QC'd by NIEHS/NTP
Inactive04.95490.5492-6.77071.540 0 0 0 0 0 0 0 0 0 1 0 0 11.3669-1.0856-0.77651.12421.70580.7901-1.98696.09015.26593.2331-7.9279-28.3694-1.3017-10.22551.3669QC'd by NIEHS/NTP
Inactive04-5.5826-4.0359-4.4476-11.3473-11.9097-1.5507-10.1535-3.36261.3234-0.4426-13.9824-5.2512-18.0387-15.3022-5.5826QC'd by NIEHS/NTP
Inhibitor39.810751.900420Partial curve; partial efficacy-4.43.990.9828-50.13811.7623-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0-49.45943.1993-0.02692.7134-1.98075.29460.2133-0.1387-0.26252.47080.17772.53720.4925-30.4729-49.4594QC'd by NIEHS/NTP
Inactive02.33320.6977-10.8456140 0 0 0 0 0 1 0 0 0 0 1 0 1-1.1266-1.46111.2528-0.03690.02955.5889-3.03576.75064.5747-1.4797-0.1821-9.6414-1.4402-9.8713-1.1266QC'd by NIEHS/NTP
Inactive0414.60080.5397-1.6708-0.4130.96947.4259-2.25855.08697.9351-2.4752-5.6365.39961.849-2.487114.6008QC'd by NIEHS/NTP
Inactive00.70.5791-8.9231440 0 0 0 0 0 1 0 0 0 0 0 0 12.80633.51535.19381.41166.33634.612.742912.44016.0481-0.14110.3707-1.47812.4968-5.76932.8063QC'd by NIEHS/NTP
Inactive04-17.8369-10.5115-2.5586-8.8158-26.0957-0.4819-9.7892-2.01490.27332.7166-17.2183-0.47591.0932-12.7028-17.8369QC'd by NIEHS/NTP
Inactive04.95490.4427-9.7222-1.541 0 1 0 0 0 0 0 0 0 0 0 0 0-13.1018-5.53920.00687.73370.45884.0455-12.3759-6.57240.92181.9145-11.3469-7.6261-8.5179-8.6226-13.1018QC'd by NIEHS/NTP
Inactive03.1320.7434-16.07841.540 0 0 0 0 0 0 0 0 0 0 0 0 13.99653.3921-1.15561.97152.01773.8894-2.6092.87572.72384.1025-3.54462.1635-3.6983-12.9823.9965QC'd by NIEHS/NTP
Inactive047.53724.3881-20.20115.5178-1.37582.0045-1.44014.9593-2.11221.3726-3.0011-3.06771.18832.18177.5372QC'd by NIEHS/NTP
Inactive0411.45250.2692-0.1403-0.3748-11.74892.8347-5.054616.89840.0513.829-3.6094-0.51978.0326-1.547611.4525QC'd by NIEHS/NTP
Inactive049.99361.71397.16916.3352-0.34329.148-5.8673-1.564112.6111.82378.2616-0.66541.73632.63199.9936QC'd by NIEHS/NTP
Inactive0410.2340.52521.3877-1.9626-0.9425.6494-0.276911.70528.3766.8657-0.149-0.19442.6788-6.419210.234QC'd by NIEHS/NTP
Activator22.387233.89380Complete curve; partial efficacy; poor fit-4.652.25260.715133.99630.10251.40 0 0 0 0 0 0 0 0 0 0 0 0 025.52240.4272-0.9219-0.128-2.10618.1765-1.5863-10.226512.16486.8628-0.3193-6.515517.608732.268925.5224QC'd by NIEHS/NTP
Inactive049.98485.58260.0396-1.5504-1.30043.2953.988212.27428.06469.11922.031.29227.4225-2.99749.9848QC'd by NIEHS/NTP
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: PolK100
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were then added to start the reaction and kinetically read twice at 0 min and 10 min on the Viewlux reader
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0007732774 uMActivity at 0.00163 uMActivity at 0.00369 uMActivity at 0.00818 uMActivity at 0.020 uMActivity at 0.030 uMActivity at 0.047 uMActivity at 0.101 uMActivity at 0.151 uMActivity at 0.243 uMActivity at 0.477 uMActivity at 0.759 uMActivity at 1.287 uMActivity at 2.393 uMActivity at 3.818 uMActivity at 6.336 uMActivity at 11.99 uMActivity at 19.37 uMActivity at 31.37 uMActivity at 60.11 uMActivity at 107.2 uMActivity at 158.4 uMActivity at 229.0 uMCompound QC
Inactive40 0 0 0 01.4694-3.5669-6.2352.85861.80421.4694QC'd by "Chem Div"
Inactive40 0 0 0 0-4.26318.22188.081110.2927-3.9947-4.2631QC'd by "Chem Div"
Inactive40 0 0 0 06.03690.3398-2.1048-8.1695-3.68226.0369QC'd by "Chem Div"
Inactive4-2.05651.7294-3.5894-1.2575-0.5402-2.0565QC'd by "Chem Div"
Inactive40 0 0 0 12.31491.00484.6369-1.9963-3.35432.3149QC'd by "Chem Div"
Inactive47.27487.15156.13721.51975.23327.2748QC'd by "Chem Div"
Inactive40 0 0 0 01.006-3.3873-7.786-9.3037-9.17611.006QC'd by "Chem Div"
Inactive40 0 0 0 0-0.0368-9.4458-10.5155-9.0065-12.9141-0.0368QC'd by "Chem Div"
Inactive40 0 0 0 02.6-7.8084-12.3007-2.0954-6.68872.6QC'd by "Chem Div"
Inactive40 0 0 0 0-11.4867-18.9051-17.4955-19.0735-9.6682-11.4867QC'd by "Chem Div"
Inactive40 0 0 0 0-7.5605-17.2173-11.0038-16.5656-22.4025-7.5605QC'd by "Chem Div"
Inactive4-7.5451-1.1939-1.3084-5.8268-5.3206-7.5451QC'd by "Chem Div"
Inactive40 0 0 0 1-5.5852-4.3753-1.0046-3.1641-10.1524-5.5852QC'd by "Chem Div"
Inactive40 0 0 0 01.1172-6.03917.01189.04461.65331.1172QC'd by "Chem Div"
Inactive42.33591.25181.6626-0.9325-0.91942.3359QC'd by "Chem Div"
Inactive40 0 0 0-19.53540.3984-4.11472.1883-19.5354QC'd by "Chem Div"
Inactive4-5.6552-4.6769-1.9378-0.5867-3.224-5.6552QC'd by "Chem Div"
Inactive4-11.3738-10.4148-13.8912-10.4252-7.8961-11.3738QC'd by "Chem Div"
Inactive4-6.1571-8.7102-2.9113-5.2229-3.4369-6.1571QC'd by "Chem Div"
Inactive40 0 0 0 1-7.3803-8.8177-11.1654-6.5301-15.9483-7.3803QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0993-0.0315-0.0456-0.0314-0.0445-0.0993QC'd by "SIGMA"0
Inactive04-0.0413-0.330.9732-0.1408-0.2626-0.0413QC'd by "SIGMA"0
Inactive043.0E-4-0.0951-0.0908-0.0608-0.01023.0E-4QC'd by "SIGMA"0
Inactive040.00362.0E-4-0.1154-0.1852-0.02580.0036QC'd by "SIGMA"0
Inactive04-0.08410.02920.0072-0.0606-0.0747-0.0841QC'd by "SIGMA"0
Inactive04-0.0562-0.02190.0027-0.0792-0.1435-0.0562QC'd by "SIGMA"0
Inactive04-0.0228-0.2225-0.17238.0E-4-0.2899-0.0228QC'd by "SIGMA"0
Inactive04-0.10910.0012-0.0968-0.007-0.2223-0.1091QC'd by "SIGMA"0
Inactive04-0.03890.07040.0162-0.0035-0.0387-0.0389QC'd by "SIGMA"0
Inactive040.0777-0.1888-0.0421-0.0179-0.13070.0777QC'd by "SIGMA"0
Inactive04-0.1076-0.1771-0.0039-0.04160.0041-0.1076QC'd by "SIGMA"0
Inactive04-0.0441-0.05340.0039-0.0433-0.1015-0.0441QC'd by "TCI"0
Inactive04-0.42250.18470.0082-0.0822-0.0703-0.4225QC'd by "SIGMA"0
Inactive040.0630.0914-0.00420.0899-0.04430.063QC'd by "SIGMA"0
Inactive040.21370.17290.0260.23310.10530.2137QC'd by "SIGMA"0
Inactive04-0.0274-0.01920.12090.04090.0156-0.0274QC'd by "SIGMA"0
Inactive040.0634-0.01480.0720.08030.08560.0634QC'd by "SIGMA"0
Inactive040.0335-0.04990.1012-0.00170.26310.0335QC'd by "SIGMA"0
Inactive04-0.0334-0.0211-0.0049-0.03310.19-0.0334QC'd by "SIGMA"0
Inactive040.15920.01470.11910.10190.12680.1592QC'd by "SIGMA"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1742-0.0105-0.0707-0.708-0.8608-0.1742QC'd by "NCI"0
Inactive04-0.15950.087-0.0389-0.0424-0.0089-0.1595QC'd by "NCI"0
Inactive040.17150.56230.2590.06620.03240.1715QC'd by "NCI"0
Inactive040.04060.1038-4.0E-40.08940.12640.0406QC'd by "SigmaAldrich"0
Inactive040.439-0.1165-0.2370.53740.0650.439QC'd by "NCI"0
Inactive04-0.1787-0.0681-0.0763-0.05880.0674-0.1787QC'd by "NCI"0
Inactive04-0.26880.03020.2349-0.1201-0.1287-0.2688QC'd by "NCI"0
Inactive04-0.1086-0.2195-0.0573-0.14660.1358-0.1086QC'd by "NCI"0
Inactive04-0.1833-0.03-0.0379-0.4701-0.1431-0.1833QC'd by "NCI"0
Inactive04-0.9523-1.1611-0.9118-1.0013-1.0781-0.9523QC'd by "Labotest"0
Inactive04-0.2307-0.10680.4032-0.0433-0.0679-0.2307QC'd by "NCI"0
Inactive040.06170.30390.1775-0.00510.08570.0617QC'd by "NCI"0
Inactive04-0.1350.1614-0.083-0.1721-0.0432-0.135QC'd by "NCI"0
Inactive040.2214-0.6929-0.11650.0685-0.05560.2214QC'd by "NCI"0
Inactive04-0.2027-0.05290.0564-0.9701-0.3154-0.2027QC'd by "NCI"0
Inactive040.06990.0444-0.03810.03760.19960.0699QC'd by "NCI"0
Inactive040.0459-0.04550.12930.11980.02850.0459QC'd by "NCI"0
Inactive04-0.0306-0.0309-0.01430.02940.0175-0.0306QC'd by "Chembridge"0
Inactive04-0.02680.23620.2368-0.0791-0.0097-0.0268QC'd by "NCI"0
Inactive040.0114-0.9843-0.7454-0.13590.21030.0114QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B1
External ID: CHEMBL3039488
Protocol: N/A
Comment: Journal: Mol Pharmacol
Year: 2013
Volume: 83
Issue: 6
First Page: 1257
Last Page: 1267
DOI: 10.1124/mol.112.084152

Target ChEMBL ID: CHEMBL1697668
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=65.85%
Inhibition=63.37%
Inhibition=75.25%
Inhibition=97.38%
Inhibition=105.26%
Inhibition=97.94%
Inhibition=105.32%
Inhibition=99.4%
Inhibition=101.01%
Inhibition=86.27%
Inhibition=80.06%
Inhibition=89.01%
Inhibition=120.91%
Inhibition=102.46%
Inhibition=101.26%
Inhibition=90.74%
Inhibition=113.76%
Inhibition=82.92%
Inhibition=126.2%
Inhibition=116.63%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PXR286
Protocol: Assay Protocol Summary:

rPXR cells were dispensed at 2,000 per well in 5uL of assay medium into white, solid-bottom 1536-well plates using a Multidrop Combi dispenser (Thermo Scientific). The assay plates were incubated at 37 C for 5hr before transferring 23 nL of test compounds dissolved in DMSO and positive control via Pintool station (Wako). The assay plates were incubated at 37 C for 24 hr. Then 5ul One-Glo assay reagent (Promega) was added to each plate by a Flying Reagent Dispenser (FRD, Aurora Discovery) and following 30 min incubation at room temperature, luciferase activity was quantified on a ViewLux plate reader (Perkin Elmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000589862 uM-Replicate_1Activity at 0.0001318894 uM-Replicate_1Activity at 0.0002737151 uM-Replicate_1Activity at 0.0006007706 uM-Replicate_1Activity at 0.00134 uM-Replicate_1Activity at 0.00300 uM-Replicate_1Activity at 0.00672 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.075 uM-Replicate_1Activity at 0.168 uM-Replicate_1Activity at 0.376 uM-Replicate_1Activity at 0.840 uM-Replicate_1Activity at 1.878 uM-Replicate_1Activity at 4.198 uM-Replicate_1Activity at 9.215 uM-Replicate_1Activity at 20.60 uM-Replicate_1Activity at 46.08 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0000589862 uM-Replicate_2Activity at 0.0001318894 uM-Replicate_2Activity at 0.0002737151 uM-Replicate_2
Inactive04-3.974-9.328860.951-0.8603-0.9791-2.2478-0.1592-1.4088-1.4481-1.8486-0.56011.39020.8307-3.1736-2.981-3.974QC'd by SigmaAldrich0
Inactive043.1534-0.744658.40124.4946-1.18473.15480.11175.19134.7194-1.0882-0.90064.4503-0.4371-0.77575.21373.1534QC'd by SigmaAldrich0
Inactive04-5.2526-5.53861.08640.5214-4.1668-1.27410.48080.04735.76251.7051-6.3754-3.9752-7.292-1.7334-3.7106-5.2526QC'd by SigmaAldrich0
Inactive04-0.1805-2.11340.9447-1.0372-0.1056-2.3955-1.3378-0.58666.0906-2.42671.87880.15168.4525-2.4041-0.9412-0.1805QC'd by SigmaAldrich0
Inactive04-1.9424-2.4179-0.3918-0.79-3.4924-2.5354-0.5237-1.4223-1.9567-1.8651-2.87791.1469-1.8962-1.32721.3672-1.9424QC'd by SigmaAldrich0
Inactive04-0.96040.6093-2.0102-0.73351.04023.8072-0.1171-0.87910.122-1.2586-1.85814.4256-2.2922-0.5193-1.9201-0.9604QC'd by SigmaAldrich0
Inactive04-0.27590.90641.44224.3599-2.02921.1958-1.22340.8684-0.30950.00191.2382-1.8524-0.96436.612-0.6136-0.2759QC'd by SigmaAldrich0
Inactive04-2.1312-4.1108-4.64521.48521.53390.0986-5.752.093-1.9236-1.2325-2.5452-3.4857-1.2862-3.6629-2.5287-2.1312QC'd by SigmaAldrich0
Activator35.4813117.001910Single point of activity-4.454.95490.9804115.0571-1.944830 0 0 0 0 0 0 0 0 0 0 0 0 0 090.9388-4.9438-0.9268-1.40840.9252-0.46771.1094-0.26281.001-1.2766-1.5816-2.1281-1.8883-0.9911-5.118390.9388QC'd by SigmaAldrich0
Inactive04-4.1822-3.6325-3.5602-2.91630.0447-2.6779-1.3593-2.5857-2.3592-0.66060.749-2.2427-3.6756-3.0051-1.3743-4.1822QC'd by SigmaAldrich0
Inactive04-2.6279-4.8158-0.1203-2.9424-0.0921-2.2587-6.30130.1866-2.91980.8195-0.60312.3419-4.6049-2.8657-0.7914-2.6279QC'd by SigmaAldrich0
Inactive04-1.2207-0.5581-0.9531-0.8562-1.4371-1.4349-1.5765-0.22630.76450.9213-1.6138-0.1911-0.9498-2.7409-1.4097-1.2207QC'd by SigmaAldrich0
Inactive04-2.3128-4.2459-3.4033-1.2688-1.74330.37311.1123-1.9559-1.6595-0.2028-1.1571-2.3458-1.8269-4.2402-0.8281-2.3128QC'd by REIDEL0
Inactive04-1.7557-1.2433-1.7686-3.5045-0.2539-1.0053-0.0425-2.5397-0.7268-0.0788-1.8630.6531-3.0944-2.62431.2892-1.7557QC'd by SigmaAldrich0
Inactive04-0.7562-0.0746-0.0549-2.8676-0.7103-0.6663-0.05551.10870.0191-0.57515.36725.4013-1.2833-1.13341.0935-0.7562QC'd by Specs0
Inactive04-5.90322.5281-0.85732.47080.0415-3.6103-5.7684-4.7375-1.5577-5.291-0.1366-0.241911.2909-5.1799-3.7222-5.9032QC'd by Specs0
Inactive04-3.9423-0.3132-1.5849-0.1592-0.591-1.4382-1.21962.9888-1.8665-2.5331-0.99452.98180.41350.06252.684-3.9423QC'd by Specs0
Inactive04-5.2212-4.071-0.5585-1.973-2.5453-0.2782-3.8559-0.5105-2.3215-5.8762.1765-3.8179-5.09720.3696-4.1897-5.2212QC'd by Specs0
Inactive04-2.4892-0.7868-1.8125-3.067-2.1410.1978-6.3727-4.8142-3.7131-2.82790.7475-0.7119-3.17291.5374-5.2455-2.4892QC'd by Tripos0
Inactive048.9671-1.04580.0065-0.0295-1.3945-1.2885-0.2262-1.50034.1559-0.35445.78863.8330.07373.91958.30648.9671QC'd by Vitas0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRA481
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/6 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514703 uM-Replicate_1W460-Activity at 0.0001157795 uM-Replicate_1W460-Activity at 0.0002347639 uM-Replicate_1W460-Activity at 0.0005064679 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.18 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.15 uM-Replicate_1W460-Activity at 213.3 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive040.7562-2.0191-2.8763-0.9026-3.551-0.7809-0.2770.3016-2.05597.6695-0.4571-0.4785-0.3067-3.19312.29950.7562102.72020.5091-13.21010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8015
Inconclusive2.683243.355504.95490.33697-1.259840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.13651.0101-0.5652-4.3951-0.2458-3.9615-0.72250.0703-5.2165-4.71332.5855-0.82580.39810.8412-1.08125.1365103.06540.430911-0.15540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4779
Inactive00.9310.515-2.2498140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.19170.0432-0.94582.66191.9187-0.00912.6540.7197-0.8071-0.0436-0.1456-2.86940.2333-3.1248-1.627-2.19171040.5349
Cytotoxic23.914564.59580Partial curve; partial efficacy-4.72133.1320.9596-43.45790.2745-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.3622.89331.82591.0907-0.1463-0.10590.92180.09150.19131.3078-6.7647-0.7119-0.62320.4675-17.992-39.362100.30.5041-9.1529140 0 0 0 0 0 0 0 0 0 0 0 0 0 13.6116
Inactive00.50.455-21.31571.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.42971.0157-1.7522.7232.69846.869-3.71430.19816.1321-2.0281-8.9254-4.3551-0.3757-5.1288-2.2826-14.4297100.20.470911.5-5.046140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.922
Inconclusive15.08948.866903.51170.44866.5-1.011940 0 0 0 0 0 0 0 0 0 0 0 0 0 05.50351.07060.905-0.25830.69930.4392-0.1511-3.58922.2605-4.5752-0.49010.3402-2.2626-5.42666.35045.5035103.1320.5006-12.72791.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.019
Activator0.095244.78110Single point of activity-7.02134.95490.971588.6934-1.347630 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.2744-4.73250.61890.21280.81980.5686-0.35281.205386.9543-3.9984-3.1116-0.3361-4.4875-4.0498-7.4011-0.27440Single point of activity-7.02134.95490.969543.878-0.903130 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.1232
Inactive043.93180.3895-0.21130.182-0.9258-0.4412-3.95122.1721-0.1688-5.0997-0.15442.3995-4.165-0.19191.89093.9318104-1.6204
Inactive04.95490.4549-2.1971140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.39480.2258-0.38513.3271.6718-0.0652.57751.6671-0.09210.011-0.24882.0368-2.0108-3.4976-0.2290.3948103.51170.49812-0.310640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5444
Inactive04.95490.49990.779540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.19890.56481.7838-0.99043.56074.2105-1.85041.559-0.7889-0.57311.13450.3821.1458-0.6344-0.05567.19891043.2539
Inconclusive26.832542.156903.1320.6237-18.228140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.8509-0.43261.3737-0.723-1.5954-0.98793.3248-0.25092.6333-1.3551-3.191.65445.081210.7255-16.44-14.85090Complete curve; partial efficacy; poor fit-5.32134.95490.903616-1.39761.40 0 0 0 0 0 0 0 0 0 0 0 0 1 014.2731
Inactive01.3310.44069-1.315540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.7682-8.1796-1.2864-0.92690.0489-1.1023.6629-5.3855-2.0892-3.4173.63520.2376-0.11450.36824.02527.7682104.0950.645512.50.056140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.4789
Inactive04-1.77665.9446-8.071110.9483-0.66150.7628-0.19420.81740.424-0.04970.3107-1.4675-4.3278-0.9634-3.4067-1.77661040.3915
Cytotoxic30.106580.09980Single point of activity-4.57134.95490.9233-34.1878-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.15651.4442-1.42590.5602-0.5727-1.5149-1.1531-1.7711-0.5991-1.6507-0.5856-0.7334-2.4262-6.8854-0.1814-30.15650Single point of activity-4.57134.95490.964133.76670.413730 0 0 0 0 0 0 0 0 0 0 0 0 0 0123.858
Inactive04.0950.6978-0.5-7.11540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.8355-7.1792-4.2685-1.14751.1488-2.8672-0.65330.9563-0.5809-0.63290.28570.6351.0765-3.2022-0.934-0.8355104.95490.8946-0.469515.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4115
Inactive047.6683-0.213812.7411-0.95732.68175.82062.76031.9502-1.1272.6603-0.154-4.84897.2899-0.02820.21517.6683100.70.4452-6.3234340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.9779
Inactive04.95490.38580-3.382540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3426-2.7245-4.1769-2.5201-5.3186-0.55251.2952-5.152-6.9854-0.68020.87571.22690.5227-3.0321.11160.3426104-1.3858
Inactive043.5373-0.4222-4.6002-0.5607-0.0671-0.45211.69491.7648-0.6170.1086-4.2139-4.41190.48912.0611-0.44833.5373104-0.2942
Activator10.682283.89470Single point of activity-4.97133.92950.884675.0549-2.701730 0 0 0 0 0 0 0 0 0 0 0 0 0 10.7587-0.7027-0.0356-2.9874-6.5873-2.95230.4426-0.8132-2.168-2.9385-0.9678-1.866-0.243-1.378889.35110.75870Single point of activity-4.97133.990.888280.6868-3.207930 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0157
Inactive043.2274-0.4217-5.36674.2879-0.76117.993-0.6172-2.95230.12040.2389-2.49690.367-2.94147.0059-0.88663.2274103.06540.600216-1.455840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.6692
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: 1011189
Protocol:
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00737 uMActivity at 0.034 uMActivity at 0.074 uMActivity at 0.160 uMActivity at 0.236 uMActivity at 0.363 uMActivity at 0.672 uMActivity at 0.802 uMActivity at 1.176 uMActivity at 1.813 uMActivity at 3.626 uMActivity at 4.165 uMActivity at 5.886 uMActivity at 9.068 uMActivity at 18.22 uMActivity at 21.24 uMActivity at 33.77 uMActivity at 45.94 uMActivity at 91.56 uMActivity at 107.6 uMActivity at 194.3 uMActivity at 231.0 uMActivity at 0.159 uMActivity at 0.360 uMActivity at 0.847 uMActivity at 1.840 uMActivity at 9.105 uMActivity at 21.25 uMActivity at 45.98 uMActivity at 107.7 uMActivity at 0.0002950000 uMActivity at 0.00135 uMActivity at 0.00295 uMActivity at 0.00640 uMActivity at 0.00942 uMActivity at 0.014 uM
Inactive26.025701.78850.999712.5-13.525740 0 0 0 1-16.4169-13.3547-10.0454.879911.8869-16.4169
Inhibitor11.220268.575810Single point of activity-4.954.0950.9841-51.897616.6782-30 0 0 0 0-51.769712.507722.751815.0653-4.0088-51.7697
Inhibitor7.0795112.066143Partial curve; high efficacy-5.151.88510.9823-103.18038.8859-2.10 0 0 0-95.53733.23779.0024-65.3012-95.5373
Inhibitor15.8489105.509342Partial curve; high efficacy-4.810.9579-114.0492-8.5398-2.10 0 0 0 0-90.5152-4.0803-11.1572-29.099-39.1247-90.5152
Inactive16.477501.3310.9615-2.5103-18.987941 0 0 0 0 0 1-16.3315-65.7135-14.9899
Inhibitor7.0795101.797683Complete curve; high efficacy-5.154.95490.9565-95.44826.3494-1.10 0 0 0 0-94.451620.9917-9.24498.049-74.805-94.4516
Inactive12.307103.06540.5785-22.7235-10.416540 0 0 0 0-26.853-10.7637-15.6935-26.1694-15.1194-26.853
Inhibitor0.089112.386510Complete curve; partial efficacy; poor fit-7.054.95490.364-34.6437-22.2572-1.40 0 0 0 0-37.9759-25.631-39.7031-25.7241-35.5044-37.9759
Inactive10.026404.44950.7108-12.3905-2.364140 0 0 0 1-7.3774-6.9326-0.3034-11.4012-11.9921-7.3774
Inactive29.146503.06540.67871.473-27.673640 0 0 0 0 0 1-21.724-27.2731-11.0127
Inactive25.21704.95490.4619-13.2171240 0 0 0 0-8.30867.9877-27.6808-0.1174-16.8896-8.3086
Inactive12.838204.95490.3995-3.393-16.231240 0 0 0 1-15.3571-15.1609-13.0051-20.6093-11.1608-15.3571
Inhibitor35.481326.237210Partial curve; partial efficacy; poor fit-4.454.95490.6657-53.1099-26.8727-2.40 0 0 0 0-47.5916-28.5919-36.8323-19.4772-23.3034-47.5916
Inactive7.543804.95490.8451-6.8775-14.421240 0 0 0 0-6.4743-14.3323-14.5177-4.8979-9.6517-6.4743
Inactive37.81404.95490.7329-20.885116.928840 0 0 0 0 0 1-3.613.1204-26.6275
Inactive13.166504.95490.6781-12.166540 0 0 0 00.861-4.7712-15.0697-16.8054-1.02860.861
Inactive6.235504.95490.32441-5.235540 0 0 0 02.3165-3.52964.2330.0986-3.45432.3165
Inactive15.475304.95490.9575-17.3357-1.860541 0 0 0 0-15.6395-25.4707-3.6337-19.0298-16.8468-15.6395
Inactive14.093800.90.9644-15.4586-1.364840 0 0 0 1-6.1352-1.1373-3.7059-5.1536-11.2155-6.1352
Inactive04-19.0793-27.1382-31.3978
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PXR809
Protocol: Assay Protocol Summary:

DPX-2 cells were dispensed at 2,000 cells per well in 5uL of assay medium into white, solid-bottom 1536-well plates using a Multidrop Combi dispenser (Thermo Scientific). The assay plates were incubated at 37C for 5hr before transferring 23nL of test compounds dissolved in DMSO and positive control via Pintool station (Wako). The assay plates were incubated at 37C for 24hr. After 24hr compound treatment, 1uL of 3uM (final concentration) P450 substrate (P450-Glo CYP3A4 screening system with Luciferin-IPA, Promega) was added by a Flying Reagent Dispenser (FRD, Aurora Discovery). The assay plates were incubated for 3hr at 37C. Then 5ul One-Glo assay reagent (Promega) was added to each plate by an FRD and following 30 min incubation at room temperature, luciferase activity was quantified on a ViewLux plate reader (Perkin Elmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000589862 uM-Replicate_1Activity at 0.0001318894 uM-Replicate_1Activity at 0.0002737151 uM-Replicate_1Activity at 0.0006007706 uM-Replicate_1Activity at 0.00134 uM-Replicate_1Activity at 0.00300 uM-Replicate_1Activity at 0.00672 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.075 uM-Replicate_1Activity at 0.168 uM-Replicate_1Activity at 0.376 uM-Replicate_1Activity at 0.840 uM-Replicate_1Activity at 1.878 uM-Replicate_1Activity at 4.198 uM-Replicate_1Activity at 9.215 uM-Replicate_1Activity at 20.60 uM-Replicate_1Activity at 46.08 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0000589862 uM-Replicate_2Activity at 0.0001318894 uM-Replicate_2Activity at 0.0002737151 uM-Replicate_2
Inactive04.95490.71356.5-8.645241 0 0 0 0 0 0 0 0 0 0 0 0 0 02.4439-14.3895-3.8274-12.1193-11.0119-6.8641-3.7-10.1309-6.097-13.3533-8.128-6.928-13.871-0.356910.11512.4439QC'd by NCI0
Activator4.466850.030442Partial curve; partial efficacy-5.350.80.930243.3306-6.69982.20 0 0 0 0 0 0 0 0 1 0 0 0 0 038.2028-9.0614-12.2695-1.4939-8.5436-6.8241-0.6574-2.3713-5.2967-1.394123.85574.219227.156721.112830.558138.2028QC'd by NCI0
Activator12.5893100.875742Partial curve; high efficacy-4.91.13410.960798.7584-2.11722.11 0 0 0 0 0 0 0 0 0 0 0 0 0 085.57422.7311-7.3847-2.7096-8.84771.7252-2.56017.7478-1.3342-0.26787.90451.637428.191733.266459.502485.574QC'd by NCI0
Activator31.622863.506810Single point of activity-4.53.67720.726559.9077-3.599130 0 0 0 0 0 0 0 0 0 0 0 0 0 047.367-5.3233-15.77581.01327.2083.9234-10.63430.7748-5.04896.69292.9354-9.1458-21.07250.28956.24447.367QC'd by NCI0
Inactive0420.350114.6-3.582115.499913.996713.78811.670517.983121.453420.474729.791310.551342.656531.531313.884720.3501QC'd by NCI0
Inactive045.3906-3.3779-7.25131.2338-5.45743.4104-6.9624-3.5922-4.7425-3.849-1.746-1.272417.886-7.2945-7.24625.3906QC'd by NCI0
Inactive04.95490.5388-6.8058-140 0 0 0 0 0 1 0 0 0 0 0 0 1 0-5.9726-0.1257-3.5692-3.55140.3615-1.824-2.364.0193-0.92720.0949-2.12664.1281-5.5165-6.92154.4889-5.9726QC'd by NCI0
Inactive047.41872.01818.3457.92467.1954-2.4912-4.83611.937-3.33297.6228-0.33410.418726.0686-1.11458.83677.4187QC'd by NCI0
Inactive04-4.4168-9.695-9.0047-5.1906-6.1303-2.2997-6.4687-8.6664-1.7547-14.7894-13.9025-12.6128-2.7819-8.4424-4.261-4.4168QC'd by NCI0
Inactive04-9.9641-1.1651-11.1069-9.1239-8.434-2.7624-1.2811-1.7912-10.8266-4.6811-2.6953-1.7086-13.4035-10.3469-7.6443-9.9641QC'd by NCI0
Inactive00.60.384-13.7483-3.130740 0 0 0 0 0 0 0 0 0 1 1 0 0 1-0.7444-2.4168-3.0443-5.4528-4.1411-0.1089-7.5751-0.9667-5.9433-4.9717-5.2724-2.074-18.4238-16.4569-5.5278-0.7444QC'd by NCI0
Activator2.511933.618810Complete curve; partial efficacy; poor fit-5.64.95490.876829.2344-4.38441.40 0 0 0 0 0 0 0 1 0 0 0 0 0 112.0852-5.1364-9.295-4.0106-4.5581-3.2156-1.7151-1.3122-2.395316.3318-2.5158-2.568634.3416.399736.095712.0852QC'd by NCI0
Inactive04-3.4006-5.3528-13.0353-6.8312-10.9957-5.9981-11.877-7.3986-4.143-11.4393-9.1588-9.23476.4453-14.1983-7.1483-3.4006QC'd by NCI0
Inactive042.7328-0.6923-10.3862-3.2139-0.61794.0765-4.014512.0978-2.6016-3.071-4.3519-3.7299-18.09623.57844.1282.7328QC'd by NCI0
Inactive042.00942.7908-22.43-10.0566-3.2031-12.3445-9.54375.0098-9.0324-9.7989-5.7955-1.6164-18.6189-10.2414-6.58692.0094QC'd by NCI0
Activator14.125437.982310Single point of activity-4.854.95490.769733.3679-4.614430 0 0 0 0 0 0 0 0 1 0 1 0 0 1-4.626-0.9241-17.9168-1.10940.9543-3.5836-7.2425-5.62892.20830.023620.5097-7.861834.1795-5.960834.0119-4.626QC'd by NCI0
Inactive04-0.6804-10.144-16.281-8.1255-2.3874-2.9269-0.2205-12.5812-1.66977.0127-5.8533-0.4093-17.6946-13.6757-0.6729-0.6804QC'd by NCI0
Activator10-6.12.72020.7028-26.333811.902450 0 0 0 0 0 1 1 0 0 0 1 0 0 0-22.20071.23-9.0274.185429.152230.929912.945555.192571.029411.4025-11.5167-18.0155-83.7088-37.1174-22.2429-22.2007QC'd by NCI0
Inactive04-0.9068-4.3942-9.6244-1.8169-1.5787-0.1399-10.8115-4.5073-3.7109-4.2349-2.8136-5.6768-16.6853-17.8471-4.7083-0.9068QC'd by NCI0
Activator15.848947.490921Partial curve; partial efficacy-4.81.96730.934446.2675-1.22342.20 0 0 0 0 0 0 0 0 0 0 1 1 0 041.89033.3855-9.9204-1.35731.6013-0.52290.1617-5.71550.33743.4536-0.05-1.180932.7909-4.832427.017841.8903QC'd by NCI0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PXR790
Protocol: Assay Protocol Summary:

DPX-2 cells were dispensed at 2,000 cells per well in 5uL of assay medium into white, solid-bottom 1536-well plates using a Multidrop Combi dispenser (Thermo Scientific). The assay plates were incubated at 37C for 5hr before transferring 23nL of test compounds dissolved in DMSO and positive control via Pintool station (Wako). The assay plates were incubated at 37C for 24hr. Then 5ul One-Glo assay reagent (Promega) was added to each plate by a Flying Reagent Dispenser (FRD, Aurora Discovery) and following 30 min incubation at room temperature, luciferase activity was quantified on a ViewLux plate reader (Perkin Elmer).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000490421 uM-Replicate_1Activity at 0.0001096552 uM-Replicate_1Activity at 0.0002275716 uM-Replicate_1Activity at 0.0004994913 uM-Replicate_1Activity at 0.00112 uM-Replicate_1Activity at 0.00250 uM-Replicate_1Activity at 0.00558 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.028 uM-Replicate_1Activity at 0.062 uM-Replicate_1Activity at 0.140 uM-Replicate_1Activity at 0.312 uM-Replicate_1Activity at 0.698 uM-Replicate_1Activity at 1.561 uM-Replicate_1Activity at 3.491 uM-Replicate_1Activity at 7.661 uM-Replicate_1Activity at 17.13 uM-Replicate_1Activity at 38.31 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0000490421 uM-Replicate_2Activity at 0.0001096552 uM-Replicate_2Activity at 0.0002275716 uM-Replicate_2
Activator15.848959.951210Partial curve; partial efficacy; poor fit-4.81.82650.877461.25491.30372.40 0 0 0 0 0 0 0 0 0 0 0 0 0 053.7271-0.68231.7483-4.8082.9313-2.51335.496-3.75772.26429.67330.3944-0.899618.39385.764133.632553.7271QC'd by NCI0
Inactive045.0779-3.4523-5.2742.1631-6.3096-2.7543-0.002-4.8299-2.891715.46880.1511-2.5667-2.17345.1911-3.29045.0779QC'd by NCI0
Activator12.589351.163941Partial curve; partial efficacy-4.910.933950.402-0.76182.20 0 0 0 0 1 0 0 0 0 0 0 0 0 038.4506-0.921-1.9239-7.55160.61667.195115.0989-2.05-2.90812.62895.39954.96238.697620.036727.647838.4506QC'd by NCI0
Inactive0-4.954.95490.777125-0.98540 0 0 0 1 0 0 0 0 0 0 1 0 0 024.7164-7.1527-5.6887-8.737511.164237.8441-0.08210.4805-2.6471-1.1076-2.04133.828129.41372.279522.831624.7164QC'd by NCI0
Inactive01.13410.673311-1.416440 0 0 0 0 0 0 1 0 0 0 0 0 0 014.9939-3.02270.79572.2319-0.5501-1.4566-4.097-2.586926.13670.26185.83646.69784.333315.4223.212514.9939QC'd by NCI0
Inactive04.0950.847717-3.385440 0 0 0 0 1 0 0 0 0 0 0 0 0 014.07-0.8931-4.8261-5.86191.2723-2.95769.0202-6.5712-3.2723-4.1726-3.7288-3.0549-1.6184-3.75660.248414.07QC'd by NCI0
Inactive01.47810.80320-3.180340 0 0 0 0 0 0 0 0 0 0 0 0 0 016.4279-7.483-9.3169-0.6667-5.3067-3.2159-5.44041.117-2.0331-0.1741-2.90320.00570.97550.94649.690216.4279QC'd by NCI0
Inactive043.75390.9868-1.5283-3.4621-0.90848.31680.9851-1.74512.71373.43286.0512-1.6207-1.64580.08311.84483.7539QC'd by NCI0
Inactive04.95490.863522-4.804540 0 0 0 0 0 0 0 0 0 0 0 0 0 015.7958-3.4609-7.4015-4.9865-7.7538-4.3882-5.1057-6.7656-0.9726-3.9284-5.4513-2.8842-5.6314-1.0667-5.573315.7958QC'd by NCI0
Inactive041.4086-4.4036-2.4109-7.74896.4763-7.6380.174-6.71970.46711.45832.0576-3.3539-7.1554-0.70262.6131.4086QC'd by NCI0
Inactive04-9.384-4.0561-2.7545-6.3994-5.5217-4.1428-7.4937-7.9866-9.5528-8.7867-7.5887-7.8225-7.2135-5.035-3.2217-9.384QC'd by NCI0
Activator28.183867.994740Partial curve; partial efficacy-4.553.1320.908170.93322.93852.20 0 0 0 0 0 0 0 0 0 0 0 0 0 055.117912.6951.6697-1.96130.07128.98173.53718.44021.6433-0.60023.5879-1.57481.1597.055613.473855.1179QC'd by NCI0
Inactive04.95490.70310.51.19841 0 0 1 0 0 0 0 0 0 0 0 0 0 09.41974.7255-0.5467-1.9184-4.1230.6655.0433-0.18970.03973.7954-0.57721.52524.16670.437811.17379.4197QC'd by NCI0
Inactive04.95490.659416.5-1.795140 0 0 0 0 1 0 0 0 0 0 0 0 0 14.6336-1.88261.0621-6.3511-6.9126-2.916612.21291.15490.55351.87884.9842-4.8151-2.023622.85839.86414.6336QC'd by NCI0
Inactive04.95490.42588.5-4.680740 1 0 0 1 0 0 0 0 0 0 0 0 0 010.2594-1.805224.7966-8.1043-0.170728.6224-3.20174.5109-6.7032-4.2084-3.899-17.23394.834917.3465-3.045310.2594QC'd by NCI0
Activator11.220269.236910Partial curve; partial efficacy; poor fit-4.953.51170.843472.15332.91642.40 0 0 0 0 0 0 0 0 0 0 0 0 0 131.62293.36595.2585-7.153-0.42729.32782.0821-0.90496.7963-2.1992.192320.8663-0.421917.788559.324231.6229QC'd by NCI0
Inactive0414.0466-1.884122.0231-5.62386.00098.23436.4730.97758.64945.08210.3952-3.656325.64887.71111.597914.0466QC'd by NCI0
Inactive04.0950.8568-14.437117.961641 0 1 0 0 0 0 0 0 0 0 0 0 0 0-13.1617-1.7396.3876-2.075223.471717.87557.097931.665922.938210.6453-8.6417-11.9247-15.2104-16.5395-14.4792-13.1617QC'd by NCI0
Inactive040.9671-1.7585-5.31522.7263-7.3382-3.4417-6.1416-9.3224-3.6845-5.25088.5321-6.3029-4.6372-11.8150.38770.9671QC'd by NCI0
Activator15.848931.568410Single point of activity-4.82.18760.727331.0491-0.519331 0 0 0 0 0 0 0 0 0 0 0 0 0 034.232516.9189-1.89583.8144-1.0467-1.05620.354-6.6992-1.56051.88125.0507-4.0354-7.67515.43238.375134.2325QC'd by NCI0